☰

Santosh Kesari - Publications

Affiliations: 
Neurosciences University of California, San Diego, La Jolla, CA 
Tree Info Grants Similar researchers PubMed Report error

245/500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Goldman S, Margol A, Hwang EI, Tanaka K, Suchorska B, Crawford JR, Kesari S. Safety of Tumor Treating Fields (TTFields) therapy in pediatric patients with malignant brain tumors: Post-marketing surveillance data. Frontiers in Oncology. 12: 958637. PMID 36072789 DOI: 10.3389/fonc.2022.958637  0.303
2021 Park JH, de Lomana ALG, Marzese DM, Juarez T, Feroze A, Hothi P, Cobbs C, Patel AP, Kesari S, Huang S, Baliga NS. A Systems Approach to Brain Tumor Treatment. Cancers. 13. PMID 34202449 DOI: 10.3390/cancers13133152  0.302
2020 Rodvold JJ, Xian S, Nussbacher J, Tsui B, Cameron Waller T, Searles SC, Lew A, Jiang P, Babic I, Nomura N, Lin JH, Kesari S, Carter H, Zanetti M. IRE1α and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cells. Scientific Reports. 10: 8348. PMID 32433555 DOI: 10.1038/S41598-020-65320-6  0.315
2020 Kim MM, Parmar HA, Schipper M, Devasia T, Aryal MP, Kesari S, O'Day S, Morikawa A, Spratt DE, Junck L, Mammoser A, Hayman JA, Lawrence TS, Tsien CI, Aiken R, et al. BRAINSTORM: A Multi-Institutional Phase I/II Study of RRx-001 in Combination with Whole Brain Radiation Therapy for Patients with Brain Metastases. International Journal of Radiation Oncology, Biology, Physics. PMID 32169409 DOI: 10.1016/J.Ijrobp.2020.02.639  0.309
2020 Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders CK, Carrillo JA, Chalasani P, Kabos P, Puhalla SL, Tkaczuk KHR, Garcia A, Ahluwalia MS, Wefel JS, Lakhani N, et al. ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31969331 DOI: 10.1158/1078-0432.Ccr-19-3258  0.326
2020 Singh VM, Fisher DM, Berz D, Schultz R, Mayer JA, Boorgula S, Nguyen M, Troung J, Dobrawa L, Gill J, Carrillo JA, Kesari S. The next generation of cerebrospinal fluid (CSF)-based molecular diagnostics: Improving sensitivity and actionability in breast and lung cancer patients with CNS involvement. Journal of Clinical Oncology. 38: e14502-e14502. DOI: 10.1200/Jco.2020.38.15_Suppl.E14502  0.363
2020 Sampson JH, Achrol A, Aghi MK, Bankiewicz K, Bexon M, Brem S, Brenner AJ, Chandhasin C, Chowdhary SA, Coello M, Das S, Han SJ, Kesari S, Merchant F, Merchant N, et al. MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control. Journal of Clinical Oncology. 38: 2513-2513. DOI: 10.1200/Jco.2020.38.15_Suppl.2513  0.365
2020 Bota DA, Duma CM, Kesari S, Piccioni DE, LaRocca RV, O'Donnell RT, Aiken RD, Carrillo JA, Hsieh C, Langford CJ, Carta K, Wang AM, Langford JA, Taylor TH, Nistor GI, et al. Abstract CT182: Adjunctive treatment of primary glioblastoma with patient-specific dendritic cell vaccines pulsed with antigens from self-renewing autologous tumor cells: A phase II trial Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct182  0.403
2019 Loya J, Zhang C, Cox E, Achrol AS, Kesari S. Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins. Cns Oncology. 8: CNS38. PMID 31747788 DOI: 10.2217/Cns-2019-0001  0.339
2019 Loya J, Zhang C, Cox E, Achrol AS, Kesari S. Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy. Cns Oncology. 8: CNS40. PMID 31747784 DOI: 10.2217/Cns-2019-0002  0.35
2019 Minev BR, Lander E, Feller JF, Berman M, Greenwood BM, Minev I, Santidrian AF, Nguyen D, Draganov D, Killinc MO, Vyalkova A, Kesari S, McClay E, Carabulea G, Marincola FM, et al. First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells. Journal of Translational Medicine. 17: 271. PMID 31426803 DOI: 10.1186/S12967-019-2011-3  0.342
2019 Sivakumar W, Barkhoudarian G, Lobo BM, Zhang X, Zhao F, Eisenberg A, Kesari S, Krauss H, Cohan P, Griffiths C, Wollman R, Chaiken L, Kelly DF. Strategy and technique of endonasal endoscopic bony decompression and selective tumor removal in symptomatic skull base meningiomas of the cavernous sinus and Meckel's cave. World Neurosurgery. PMID 31226453 DOI: 10.1016/J.Wneu.2019.06.073  0.328
2019 Piccioni DE, Achrol AS, Kiedrowski LA, Banks KC, Boucher N, Barkhoudarian G, Kelly DF, Juarez T, Lanman RB, Raymond VM, Nguyen M, Truong JD, Heng A, Gill J, Saria M, ... ... Kesari S, et al. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. Cns Oncology. PMID 30855176 DOI: 10.2217/Cns-2018-0015  0.378
2019 Cobbs C, McClay E, Duic JP, Nabors LB, Murray DM, Kesari S. An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US. Cns Oncology. 8. PMID 30547676 DOI: 10.2217/Cns-2018-0013  0.304
2019 Carrillo JA, Kesari S. Is re-radiation for glioblastoma after progression associated with increased survival: to treat or not to treat? Translational Cancer Research. 8: 4-6. DOI: 10.21037/25233  0.39
2019 Mason WP, Kesari S, Stupp R, Aregawi DG, Piccioni DE, Roth P, Desjardins A, Reich SD, Casadebaig M, Elias I, Winograd B, Levin N, Bota DA. Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 37: 2021-2021. DOI: 10.1200/Jco.2019.37.15_Suppl.2021  0.351
2019 Kesari S, Juarez T, Carrillo J, Truong J, Nguyen M, Heng A, Gill J, Nguyen H, Nomura N, Grigorian B, Hou S, Schmid A, Desai N. RBTT-01. A PHASE 2 TRIAL WITH ABI-009 (NAB-SIROLIMUS) AS SINGLE-AGENT AND COMBINATIONS IN RECURRENT HIGH-GRADE GLIOMA (rHGG) AND IN NEWLY DIAGNOSED GLIOBLASTOMA (ndGBM) Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.913  0.313
2019 Chang A, Gardner S, Jaboin J, Leary S, Mola RLD, McClay E, Murray DM, Nazemi K, Panandiker AP, Salacz M, Stapleton S, Kesari S, Prados M. Pdct-07. Early Results Of The Emulate Therapeutics Hælo™ System In Pediatric Brain Tumors Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.770  0.352
2019 Barkhoudarian G, Blondin N, Chowdhary S, Fonkem E, Vaillant B, Kesari S. Actr-69. Feasibility Study Of The Emulate Therapeutics™ Voyager System In Patients With Newly Diagnosed Glioblastoma Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.110  0.315
2019 Barkhoudarian G, Badruddoja M, Blondin N, Chen R, Chowdhary S, Cobbs C, Dowling A, Duic P, Flores JP, Fonkem E, McClay E, Nabors L, Salacz M, Vaillant B, Kesari S. Actr-68. Feasibility Study Of The Emulate Therapeutics™ Voyager System In Patients With Recurrent Glioblastoma (Gbm) Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.109  0.339
2018 George E, Kijewski MF, Dubey S, Belanger AP, Reardon DA, Wen PY, Kesari S, Horky L, Park MA, Huang RY. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. Ajr. American Journal of Roentgenology. 1-6. PMID 30332289 DOI: 10.2214/Ajr.18.19988  0.325
2018 Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, et al. Profiles of Brain Metastases: Prioritization of Therapeutic Targets. International Journal of Cancer. PMID 29923182 DOI: 10.1002/Ijc.31624  0.385
2018 Hashimoto Y, Penas-Prado M, Zhou S, Wei J, Khatua S, Hodges TR, Sanai N, Xiu J, Gatalica Z, Kim L, Kesari S, Rao G, Spetzler D, Heimberger A. Rethinking medulloblastoma from a targeted therapeutics perspective. Journal of Neuro-Oncology. PMID 29869738 DOI: 10.1007/S11060-018-2917-2  0.33
2018 Everson RG, Hashimoto Y, Freeman JL, Hodges TR, Huse J, Zhou S, Xiu J, Spetzler D, Sanai N, Kim L, Kesari S, Brenner A, De Monte F, Heimberger A, Raza SM. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. Journal of Neuro-Oncology. PMID 29846894 DOI: 10.1007/S11060-018-2891-8  0.303
2018 Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, ... ... Kesari S, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine. 16: 142. PMID 29843811 DOI: 10.1186/S12967-018-1507-6  0.32
2018 Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu P, et al. Durable Complete Responses in Some Recurrent High Grade Glioma Patients Treated with Toca 511 & Toca FC. Neuro-Oncology. PMID 29762717 DOI: 10.1093/Neuonc/Noy075  0.359
2018 Ferguson SD, Zhou S, Xiu J, Hashimoto Y, Sanai N, Kim L, Kesari S, de Groot J, Spetzler D, Heimberger AB. Ependymomas overexpress chemoresistance and DNA repair-related proteins. Oncotarget. 9: 7822-7831. PMID 29487694 DOI: 10.18632/Oncotarget.23288  0.304
2018 Bota DA, Kesari S, Piccioni DE, Aregawi DG, Roth P, Stupp R, Desjardins A, Reich SD, Elias I, Li M, Levin N, Winograd B, Mason WP. A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E14083  0.363
2018 Walbert T, Lavy-Shahaf G, Toms SA, Kesari S. Abstract CT100: Tumor treating fields (TTFields) on health-related quality of life (HRQoL) in ndGBM: An exploratory analysis of the EF-14 phase III trial Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct100  0.342
2018 Babic I, Nomura N, Glassy E, Nurmemmedov E, Yenugonda V, Glassy M, Kesari S. Abstract 3828: Pritumumab mAb binds cell surface expressed vimentin on pancreatic cancer cells and inhibits tumor growth Cancer Research. 78: 3828-3828. DOI: 10.1158/1538-7445.Am2018-3828  0.356
2018 Cloughesy TF, Landolfi J, Vogelbaum M, Ostertag D, Elder B, Carter B, Chen CC, Kalkanis S, Kesari S, Lai A, Lee I, Liau L, Mikkelsen T, Nghiemphu L, Piccioni D, et al. Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A085  0.409
2018 Dardis C, Phuphanich S, Sanai N, Xiu J, Mittal S, Michelhaugh S, Subramaniam D, Pandey M, Kesari S, Heimberger A, Gatalica Z, Korn WM, Sumrall A. Rare-05. Tumor Profiling Reveals Epithelial-To-Mesenchymal Transition (Emt) And Enhanced Immune Suppression In Gliosarcomas Relative To Glioblastoma Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.983  0.311
2018 Kim M, Parmar H, Aryal M, Schipper M, Devasia T, Kesari S, Morikawa A, Spratt D, Junck L, Hayman J, Lawrence T, Tsien C, Aiken R, Goyal S, Knox S, et al. CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES Neuro-Oncology. 20: vi63-vi63. DOI: 10.1093/Neuonc/Noy148.255  0.316
2018 Bota DA, Kesari S, Piccioni D, Aregawi D, Roth P, Stupp R, Desjardins A, Reich SD, Elias I, Li M, Levin N, Winograd B, Mason W. ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.073  0.323
2018 Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. Actr-26. A Feasibility Study Of The Nativis Voyager® System In Patients With Newly Diagnosed Glioblastoma (Gbm) Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.059  0.331
2018 Bexon MF, Achrol A, Bankiewicz K, Brenner A, Butowski N, Kesari S, Merchant F, Merchant R, Randazzo D, Vogelbaum M, Zabek M, Sampson J. Understanding biological activity, tumor response and pseudoprogression in a phase-IIb study of MDNA55 in adults with recurrent or progressive glioblastoma (GB). Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy273.368  0.336
2018 Mikkelsen T, Cloughesy T, Landolfi J, Vogelbaum M, Ostertag D, Elder J, Chen C, Kalkanis S, Kesari S, Lai A, Lee I, Liau L, Nghiemphu P, Piccioni D, Accomando W, et al. 25 Durable complete responses observed in patients with recurrent high grade glioma treated with Toca 511 & Toca FC Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques. 45: S11-S11. DOI: 10.1017/Cjn.2018.290  0.405
2017 Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. Cancer. PMID 29211306 DOI: 10.1002/Cncr.31175  0.311
2017 Wang G, Benasutti H, Jones JF, Shi G, Benchimol M, Pingle S, Kesari S, Yeh Y, Hsieh LE, Liu YT, Elias A, Simberg D. Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles. Colloids and Surfaces. B, Biointerfaces. 161: 200-209. PMID 29080504 DOI: 10.1016/J.Colsurfb.2017.10.060  0.333
2017 Yenugonda V, Nomura N, Kouznetsova V, Tsigelny I, Fogal V, Nurmemmedov E, Kesari S, Babic I. A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma. Journal of Translational Medicine. 15: 210. PMID 29047383 DOI: 10.1186/S12967-017-1312-7  0.306
2017 Babic I, Nurmemmedov E, Yenugonda VM, Juarez T, Nomura N, Pingle SC, Glassy MC, Kesari S. Pritumumab, the first therapeutic antibody for glioma patients. Human Antibodies. PMID 29036806 DOI: 10.3233/Hab-170326  0.352
2017 Guo G, Gong K, Ali S, Ali N, Shallwani S, Hatanpaa KJ, Pan E, Mickey B, Burma S, Wang DH, Kesari S, Sarkaria JN, Zhao D, Habib AA. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Nature Neuroscience. PMID 28604685 DOI: 10.1038/Nn.4584  0.3
2017 Tao Z, Li S, Ichim TE, Yang J, Riordan N, Yenugonda V, Babic I, Kesari S. Cellular immunotherapy of cancer: an overview and future directions. Immunotherapy. 9: 589-606. PMID 28595516 DOI: 10.2217/Imt-2016-0086  0.375
2017 Capper D, von Deimling A, Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, et al. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. International Journal of Molecular Sciences. 18. PMID 28481241 DOI: 10.3390/Ijms18050995  0.385
2017 Wagner SC, Ichim TE, Bogin V, Min WP, Silva F, Patel AN, Kesari S. Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine. Oncotarget. PMID 28404894 DOI: 10.18632/Oncotarget.15563  0.354
2017 Kesari S, Ram Z. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. Cns Oncology. PMID 28399638 DOI: 10.2217/Cns-2016-0049  0.364
2017 Krishnan AP, Karunamuni R, Leyden KM, Seibert TM, Delfanti RL, Kuperman JM, Bartsch H, Elbe P, Srikant A, Dale AM, Kesari S, Piccioni DE, Hattangadi-Gluth JA, Farid N, McDonald CR, et al. Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma. Ajnr. American Journal of Neuroradiology. PMID 28279985 DOI: 10.3174/Ajnr.A5099  0.333
2017 Saria MG, Nyamathi A, Phillips LR, Stanton AL, Evangelista L, Kesari S, Maliski S. The Hidden Morbidity of Cancer: Burden in Caregivers of Patients with Brain Metastases. The Nursing Clinics of North America. 52: 159-178. PMID 28189161 DOI: 10.1016/J.Cnur.2016.10.002  0.309
2017 Babic I, Mukthavaram R, Jiang P, Nomura N, Glassy E, Glassy MC, Kesari S. Analysis of hybridoma and CHO-derived pritumumab for therapeutic applications. Journal of Clinical Oncology. 35: 71-71. DOI: 10.1200/Jco.2017.35.7_Suppl.71  0.325
2017 Lanman TA, Kesari S, Patel SP, Bazhenova L, Parker BA, Daniels GA, Fanta PT, Plaxe SC, Schwaederle MC, Kurzrock R, Piccioni DE. Comparison of tissue DNA to circulating tumor DNA in patients with brain metastases. Journal of Clinical Oncology. 35: e13546-e13546. DOI: 10.1200/Jco.2017.35.15_Suppl.E13546  0.35
2017 Cloughesy TF, Ostertag D, Landolfi JC, Walbert T, Vogelbaum MA, Elder JB, Bloomfield S, Carter B, Chen C, Kalkanis SN, Kesari S, Lai A, Lee I, Liau LM, Mikkelsen T, et al. Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC. Journal of Clinical Oncology. 35: e13504-e13504. DOI: 10.1200/Jco.2017.35.15_Suppl.E13504  0.395
2017 Ibrahim N, Tang S, Brenner A, Kesari S, Piccioni D, Anders C, Carillo J, Chalasani P, Kabos P, Puhalla S, Garcia A, Tkaczuk K, Lakhani N, Kumthekar P. Abstract P1-12-01: A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-12-01  0.365
2017 Babic I, Mukthavaram R, Jiang P, Glassy E, Nomura N, Pingle S, Glassy MC, Kesari S. Abstract 5611: Use of ecto-domain vimentin to target brain cancers Cancer Research. 77: 5611-5611. DOI: 10.1158/1538-7445.Am2017-5611  0.374
2017 Nguyen M, Truong J, Saria M, Kesari S. Qlif-16. Clinical And Social Challenges & Opportunities In Treating Glioblastoma With Tumor Treatment Fields, A Case Series Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.826  0.308
2017 Alton G, Beaton G, Knowles S, Guerrero A, Kesari S, Stein G. Exth-18. Ct-179 Selectively Targets Olig2-Positive Glioma Stem Cells And Demonstrates Potent Anti-Tumor Activity In Glioblastoma Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.313  0.318
2017 Ferguson S, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz M, Piccioni D, Suyun H, Davies M, Glitza I, Heymach J, et al. CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS Neuro-Oncology. 19: vi40-vi41. DOI: 10.1093/Neuonc/Nox168.158  0.311
2017 Juarez T, Boucher N, Heng A, Gill J, Nguyen M, Truong J, Saria M, Achrol A, Barkhoudarian G, Kelly D, Kesari S. Actr-62. A Phase Ii Study Of Tumor Treating Fields (Ttfields) With Temozolomide In Patients With Low-Grade Gliomas Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.051  0.351
2017 Kesari S, Tran D, Read W, Ahluwalia M, Villano J, Toms S, Zhu J, Ram Z. Actr-55. Tumor Treating Fields With Second Line Treatment Compared To Second Line Treatment Alone In Patients At First Recurrence Of Glioblastoma – A Post Hoc Analysis Of The Ef-14 Phase 3 Clinical Trial Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.046  0.338
2017 Bota D, Mason W, Kesari S, Piccioni D, Aregawi D, Desjardins A, Winograd B, Reich SD, Levin N, Trikha M. ACTR-45. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM) Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.036  0.319
2017 Barkhoudarian G, Cobbs C, McClay E, Vaillant B, Duic JP, Nabors B, Ellingson B, Sheffield D, Kesari S. Actr-41. Interim Results Of First-In-Human Study Using Nativis Voyager™ System In Patients With Recurrent Glioblastoma (Gbm) Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.032  0.314
2017 Juarez T, Boucher N, Heng A, Gill J, Nguyen M, Truong J, Saria M, Achrol A, Barkhoudarian G, Kelly D, Kesari S. Actr-33. A Phase I Dose Escalation And Central Nervous System (Cns) Pharmacokinetic Study Of Pulsatile Afatinib In Patients With Brain Cancer Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.026  0.319
2017 Sivakumar W, Lobo B, Zhang X, Zhao F, Amy E, Kesari S, Wollman R, Chaiken L, Cohan P, Griffiths C, Barkhoudarian G, Kelly D. Endonasal Endoscopic Bony Decompression, Limited Tumor Removal and Stereotactic Radiation Therapy in Invasive Parasellar Meningiomas to Improve Cranial Neuropathy and Endocrinopathy Skull Base Surgery. 78. DOI: 10.1055/S-0037-1600628  0.331
2017 Makale MT, Kesari S, Wrasidlo W. The autonomic nervous system and cancer Biocybernetics and Biomedical Engineering. 37: 443-452. DOI: 10.1016/J.Bbe.2017.05.001  0.383
2016 Sulzmaier FJ, Young-Robbins S, Jiang P, Geerts D, Prechtl AM, Matter ML, Kesari S, Ramos JW. RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics. Oncotarget. PMID 27829215 DOI: 10.18632/Oncotarget.13084  0.428
2016 Saria MG, Kesari S. Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy. Clinical Journal of Oncology Nursing. 20: 9. PMID 27668388 DOI: 10.1188/16.Cjon.S1.9-13  0.392
2016 Jiang P, Zhang P, Mukthavaram R, Nomura N, Pingle SC, Teng D, Chien S, Guo F, Kesari S. Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells. Oncotarget. PMID 27462771 DOI: 10.18632/Oncotarget.10773  0.33
2016 Stupp R, Toms SA, Kesari S. Treatment for Patients With Newly Diagnosed Glioblastoma--Reply. Jama. 315: 2348-2349. PMID 27272591 DOI: 10.1001/Jama.2016.1847  0.304
2016 Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine. 8: 341ra75. PMID 27252174 DOI: 10.1126/Scitranslmed.Aad9784  0.361
2016 Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27185373 DOI: 10.1158/1078-0432.Ccr-16-0318  0.346
2016 Wagner SC, Riordan NH, Ichim TE, Szymanski J, Ma H, Perez JA, Lopez J, Plata-Munoz JJ, Silva F, Patel AN, Kesari S. Safety of targeting tumor endothelial cell antigens. Journal of Translational Medicine. 14: 90. PMID 27071457 DOI: 10.1186/S12967-016-0842-8  0.341
2016 Xiu J, Piccioni D, Juarez T, Pingle SC, Hu J, Rudnick J, Fink K, Spetzler DB, Maney T, Ghazalpour A, Bender R, Gatalica Z, Reddy S, Sanai N, Idbaih A, ... ... Kesari S, et al. Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. Oncotarget. PMID 26933808 DOI: 10.18632/Oncotarget.7722  0.335
2016 Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, et al. A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro-Oncology. PMID 26902851 DOI: 10.1093/Neuonc/Now009  0.332
2016 Lee EQ, Muzikansky A, Drappatz J, Kesari S, Wong ET, Fadul CE, Reardon DA, Norden AD, Nayak L, Rinne ML, Alexander BM, Arvold ND, Doherty L, Stefanik J, LaFrankie D, et al. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro-Oncology. PMID 26902850 DOI: 10.1093/Neuonc/Now007  0.318
2016 Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Molecular Cancer Therapeutics. PMID 26873727 DOI: 10.1158/1535-7163.MCT-15-0795  0.349
2016 Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. PMID 26848768 DOI: 10.18632/oncotarget.7110  0.307
2016 Xiu J, Reddy SK, Kesari S, McLaughlin SE, Hohl RJ, Barger G, Heimberger AB. Comparison of molecular alteration in glioblastoma tumors from old and young patients. Journal of Clinical Oncology. 34: 2056-2056. DOI: 10.1200/Jco.2016.34.15_Suppl.2056  0.342
2016 Cloughesy TF, Aghi MK, Chen C, Elder JB, Kesari S, Kalkanis SN, Kaptain G, Landolfi JC, Mikkelsen T, Portnow J, Robbins JM, Ostertag D, Das A, Chu A, Vogelbaum MA. Encouraging survival with Toca 511 and Toca FC compared to external lomustine control. Journal of Clinical Oncology. 34: 2030-2030. DOI: 10.1200/Jco.2016.34.15_Suppl.2030  0.351
2016 Faiq N, Patel SP, Bazhenova L, Parker BA, Plaxe SC, Kurzrock R, Kesari S, Piccioni DE. Characterization of cell-free circulating tumor DNA in patients with brain metastases. Journal of Clinical Oncology. 34: 2023-2023. DOI: 10.1200/Jco.2016.34.15_Suppl.2023  0.396
2016 Kumthekar P, Tang S, Brenner AJ, Kesari S, Piccioni DE, Anders CK, Carrillo JA, Chalasani P, Kabos P, Puhalla S, Garcia AA, Tkaczuk KH, Ahluwalia MS, Lakhani NJ, Ibrahim NK. ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer. Journal of Clinical Oncology. 34: 2004-2004. DOI: 10.1200/Jco.2016.34.15_Suppl.2004  0.311
2016 Tang S, Bates S, Kesari S, Brenner A, Anders C, Garcia A, Ibrahim N, Tkaczuk K, Kumthekar P. Abstract P6-17-04: A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant taxane derivative, in breast cancer patients with recurrent CNS metastases Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-17-04  0.398
2016 Wang G, Pingle S, Kesari S, Liu Y, Simberg D. Abstract 357: Rapid harvesting of highly concentrated circulating tumor cells from bulk human blood with buoyant immuno-microbubbles Cancer Research. 76: 357-357. DOI: 10.1158/1538-7445.Am2016-357  0.377
2016 Alton G, Beaton G, Knowles S, Stein G, Mukthavaam R, Kesari S. Abstract 3030: CT179: A novel small molecule Olig2 inhibitor for the treatment of glioblastoma Cancer Research. 76: 3030-3030. DOI: 10.1158/1538-7445.Am2016-3030  0.36
2016 Babic I, Mukthavaram R, Nomura N, Pingle S, Glassy MC, Kesari S. Abstract 2357: Therapeutic potential of the natural human IgG1k antibody pritumumab Cancer Research. 76: 2357-2357. DOI: 10.1158/1538-7445.Am2016-2357  0.363
2016 Sanai N, Xiu J, Kim L, Kesari S, Zhou S, Groot Jd, Heimberger A. Rare-38. Novel Targets In Ependymal Tumors Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.701  0.338
2016 Crawford J, Dhall G, Margol A, Saria M, Kesari S. Nimg-66. Clinical Experiences Of Tumor Treating Fields (Ttfields) In Pediatric Patients With Gbm Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.577  0.346
2016 Saria M, Nguyen M, Truong J, Heng A, Boucher N, Eisenberg A, Kesari S. Nimg-63. Optimal Patient And Family Education Is Key To Improving The Efficacy Of Tumor Treating Fields Plus Chemotherapy In Treatment Of Gbm Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.574  0.329
2016 Kumthekar P, Tang S, Brenner A, Kesari S, Piccioni D, Anders C, Carrillo J, Chalasani P, Kabos P, Ahluwalia MS, Ibrahim N. Bmet-28. The Novel Brain Penetrating Peptide-Drug Conjugate Ang1005 Shows Activity In Lc Subset Of Patients With Recurrent Cns Metastasis From Breast Cancer Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.128  0.311
2016 Kumthekar P, Tang S, Brenner AJ, Kesari S, Anders CK, Carrillo JA, Chalasani P, Kabos P, Ahluwalia MS, Ibrahim NK. OS7.2 A Phase II Study of ANG1005, a novel BBB/BCB Penetratant Taxane in Patients with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now188.052  0.322
2016 Tang S, Kumthekar P, Brenner AJ, Kesari S, Piccioni D, Anders CK, Carillo JA, Chalasani P, Kabos P, Puhalla SL, Garcia A, Tkaczuk K, Ahluwalia MS, Lakhani N, Ibrahim N. ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw367.02  0.301
2015 Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. Jama. 314: 2535-43. PMID 26670971 DOI: 10.1001/Jama.2015.16669  0.39
2015 Elinzano H, Glantz M, Mrugala M, Kesari S, Piccioni DE, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, et al. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244. American Journal of Clinical Oncology. PMID 26658237 DOI: 10.1097/Coc.0000000000000247  0.348
2015 Scott BJ, Oberheim-Bush NA, Kesari S. Leptomeningeal metastasis in breast cancer - a systematic review. Oncotarget. PMID 26543235 DOI: 10.18632/Oncotarget.5911  0.328
2015 Wagner SC, Ichim TE, Ma H, Szymanski J, Perez JA, Lopez J, Bogin V, Patel AN, Marincola FM, Kesari S. Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique? Journal of Translational Medicine. 13: 340. PMID 26510973 DOI: 10.1186/S12967-015-0688-5  0.347
2015 Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. PMID 26418953 DOI: 10.18632/Oncotarget.5289  0.397
2015 Mukthavaram R, Ouyang X, Saklecha R, Jiang P, Nomura N, Pingle SC, Guo F, Makale M, Kesari S. Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres. Journal of Translational Medicine. 13: 269. PMID 26283544 DOI: 10.1186/S12967-015-0627-5  0.332
2015 Saria MG, Piccioni D, Carter J, Orosco H, Turpin T, Kesari S. Current Perspectives in the Management of Brain Metastases. Clinical Journal of Oncology Nursing. 19: 475-9. PMID 26207714 DOI: 10.1188/15.Cjon.475-478  0.34
2015 Alentorn A, Duran-Peña A, Pingle SC, Piccioni DE, Idbaih A, Kesari S. Molecular profiling of gliomas: potential therapeutic implications. Expert Review of Anticancer Therapy. 15: 955-62. PMID 26118895 DOI: 10.1586/14737140.2015.1062368  0.378
2015 Jadin L, Pastorino S, Symons R, Nomura N, Jiang P, Juarez T, Makale M, Kesari S. Hyaluronan expression in primary and secondary brain tumors. Annals of Translational Medicine. 3: 80. PMID 25992379 DOI: 10.3978/J.Issn.2305-5839.2015.04.07  0.386
2015 Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. Cell Cycle (Georgetown, Tex.). 14: 1730-7. PMID 25928476 DOI: 10.1080/15384101.2015.1033596  0.346
2015 Ichim TE, Li S, Ma H, Yurova YV, Szymanski JS, Patel AN, Kesari S, Min WP, Wagner SC. Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax™. Journal of Translational Medicine. 13: 90. PMID 25889119 DOI: 10.1186/S12967-015-0441-0  0.374
2015 Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, Johnson BE, Kesari S. A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget. 6: 4527-36. PMID 25784657 DOI: 10.18632/Oncotarget.2886  0.333
2015 Le AP, Huang Y, Pingle SC, Kesari S, Wang H, Yong RL, Zou H, Friedel RH. Plexin-B2 promotes invasive growth of malignant glioma. Oncotarget. 6: 7293-304. PMID 25762646 DOI: 10.18632/Oncotarget.3421  0.311
2015 Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle (Georgetown, Tex.). 14: 1252-9. PMID 25695927 DOI: 10.1080/15384101.2015.1014149  0.345
2015 Lyday B, Chen T, Kesari S, Minev B. Overcoming tumor immune evasion with an unique arbovirus. Journal of Translational Medicine. 13: 3. PMID 25592450 DOI: 10.1186/S12967-014-0349-0  0.353
2015 Fogal V, Babic I, Chao Y, Pastorino S, Mukthavaram R, Jiang P, Cho YJ, Pingle SC, Crawford JR, Piccioni DE, Kesari S. Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction. Oncotarget. 6: 1157-70. PMID 25528767 DOI: 10.18632/Oncotarget.2708  0.307
2015 Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Investigational New Drugs. 33: 247-53. PMID 25388940 DOI: 10.1007/S10637-014-0186-2  0.326
2015 Holcombe RF, Xiu J, Pishvaian MJ, Millis SZ, Gatalica Z, Reddy SK, Sicklick JK, Fanta PT, Kesari S, Morse MA. Tumor profiling of biliary tract carcinomas to reveal distinct molecular alterations and potential therapeutic targets. Journal of Clinical Oncology. 33: 285-285. DOI: 10.1200/Jco.2015.33.3_Suppl.285  0.325
2015 Jiang P, Mukthavaram R, Nomura N, Pingle SC, Kesari S. Anti-cancer effects of zoledronic acid on human cancer cells. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E13042  0.303
2015 Pingle SC, Juarez T, Saria MG, Kesari S. CSF pharmacokinetics of high-dose pulsatile tyrosine kinase therapy in brain cancer patients. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E13032  0.338
2015 Faiq N, Chmielecki J, Goldberg M, Stephens P, Kurzrock R, Kesari S, Piccioni DE. Analysis of BRAF alterations and molecular profiling in glioblastoma and astrocytoma. Journal of Clinical Oncology. 33: 2074-2074. DOI: 10.1200/Jco.2015.33.15_Suppl.2074  0.302
2015 Kesari S, Xiu J, Hu JL, Salacz ME, Piccioni DE, Reddy SK. Tumor profiles of brain metastases from NSCLC, breast cancer, and melanoma. Journal of Clinical Oncology. 33: 2060-2060. DOI: 10.1200/Jco.2015.33.15_Suppl.2060  0.373
2015 Xiu J, Spetzler D, Bender R, Ghazalpour A, Gatalica Z, Reddy SK, Piccioni DE, Hu JL, Glantz MJ, Kesari S. Tumor profiling on 1245 gliomas and paired tumor study on 19 high grade gliomas. Journal of Clinical Oncology. 33: 2058-2058. DOI: 10.1200/Jco.2015.33.15_Suppl.2058  0.38
2015 Armstrong TS, Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu J, Glantz MJ, Peereboom DM, Markert J, LaRocca RV, O'Rourke D, Fink KL, Kim LJ, ... ... Kesari S, et al. Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107. Journal of Clinical Oncology. 33: 2036-2036. DOI: 10.1200/Jco.2015.33.15_Suppl.2036  0.335
2015 Stupp R, Taillibert S, Kanner A, Kesari S, Toms SA, Barnett GH, Fink KL, Silvani A, Lieberman FS, Zhu J, Taylor LP, Honnorat J, Hottinger A, Chen T, Tran DD, et al. Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial. Journal of Clinical Oncology. 33: 2000-2000. DOI: 10.1200/Jco.2015.33.15_Suppl.2000  0.37
2015 Piccioni DE, Lanman RB, Nagy RJ, Talasaz A, Pingle SC, Kesari S. Analysis of cell-free circulating tumor DNA in patients with glioblastoma and other primary brain tumors. Journal of Clinical Oncology. 33: 11072-11072. DOI: 10.1200/Jco.2015.33.15_Suppl.11072  0.383
2015 Chmielecki J, Goldberg ME, Fichtenholtz A, Elvin J, Frampton GM, Ali SM, Ross JS, Morosini D, Miller VA, Piccioni D, Kesari S, Stephens PJ. Abstract 4667: The complex genomic landscape of glial tumors reveals distinct subclasses and potential therapeutic targets associated with clinical responses to targeted inhibitors Cancer Research. 75: 4667-4667. DOI: 10.1158/1538-7445.Am2015-4667  0.317
2015 Schwaederle MC, Piccioni DE, Kesari S, Husain H, Patel SP, Kurzrock R. Abstract C19: Use of liquid biopsies in clinical oncology: the UCSD Moores Cancer Center experience in 168 patients with diverse malignancies Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C19  0.389
2015 Aghi M, Vogelbaum MA, Cloughesy T, Kaptain G, Portnow J, Ostertag D, Keller MR, Niethammer A, Chu A, Kesari S. SURG-10TRANSCRANIAL TOCA 511 FOLLOWED BY TOCA FC IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA (HGG) Neuro-Oncology. 17: v216.2-v216. DOI: 10.1093/Neuonc/Nov235.10  0.351
2015 Arguello D, Abbott B, Reddy S, Gatalica Z, Kesari S, Sender L. Ptps-01Molecular Profiling Analysis Of Select Pediatric Neuroepithelial Tumors Of The Central Nervous System Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov228.01  0.387
2015 Kesari S, Landolfi J, Mikkelsen T, Aghi M, Vogelbaum MA, Elder JB, Cobbs C, Singer S, Robbins JM, Ostertag D, Jolly DJ, Chu A, Keller MR, Niethammer A, Cloughesy TF. IMCT-05COMBINABILITY OF TOCA FC AND TOCA 511 WITH CHEMOTHERAPY AND TARGETED AGENTS Neuro-Oncology. 17: v108.1-v108. DOI: 10.1093/Neuonc/Nov218.05  0.382
2015 Ostertag D, Hogan D, Vogelbaum M, Kesari S, Kalkanis S, Mikkelsen T, Landolfi J, Elder JB, Chen C, Niethammer A, Chu A, Jolly D, Gruber H, Cloughesy T. GENO-30DISTINCT GENE EXPRESSION PROFILE THAT IS NOT A KNOWN SURVIVAL PREDICTOR IN TUMORS FROM LONG-TERM HIGH GRADE GLIOMA SURVIVORS TREATED WITH A RETROVIRAL REPLICATING VECTOR ENCODING YEAST CYTOSINE DEAMINASE Neuro-Oncology. 17: v98.2-v98. DOI: 10.1093/Neuonc/Nov215.30  0.392
2015 Pingle S, Langley E, Juarez T, Saria M, Meyer G, Kim P, Kesari S. Ddel-17Csf Pharmacokinetics And Pharmacodynamics In Brain Cancer Patients On High-Dose Erlotinib Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov212.17  0.371
2015 Landolfi J, Cloughesy T, Vogelbaum MA, Kesari S, Piccioni DE, Kalkanis SN, Portnow J, Mikkelsen T, Elder JB, Baskin D, Chu A, Niethammer A, Gruber H, Cobbs C, Foltz G, et al. DDEL-08OVERALL SAFETY AND EFFICACY IN SUBJECTS WITH RECURRENT HGG TREATED ACROSS 2 TOCAGEN STUDIES - PROGNOSTIC FACTORS ASSOCIATED WITH SURVIVAL Neuro-Oncology. 17: v74.4-v75. DOI: 10.1093/Neuonc/Nov212.08  0.392
2015 Kalkanis SN, Aghi MK, Cloughsy TF, Kaptain G, Portnow J, Vogelbaum MA, Kesari S, Mikkelsen T, Elder JB, Chen CC, Piccioni D, Baskin D, Engh J, Bota D, Chiocca EA, et al. Ddel-06Preliminary Safety Of Toca 511, A Retroviral Replicating Vector, In Patients With Recurrent High Grade Glioma Across Three Separate Phase 1 Studies Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov212.06  0.394
2015 Faiq N, Lee M, Banks K, Lanman R, Pingle S, Kesari S, Piccioni D. Cbm-13Characterization Of Cell-Free Circulating Tumor Dna In Low Grade And Malignant Gliomas. Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov211.13  0.359
2015 Kesari S, Xiu J, Hu J, Salacz M, Piccioni D, Reddy S. Bmet-36Tumor Profiles Of Brain Metastases From Nsclc, Breast Cancer And Melanoma Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov208.36  0.351
2015 Kumthekar P, Bates S, Kesari S, Brenner A, Anders C, Garcia A, Ibrahim N, Tkaczuk K, Tang S. Bmet-23Ang1005, A Novel Brain-Penetrant Peptide-Taxane Conjugate, For The Treatment Of Cns Metastases From Breast Cancer Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov208.23  0.385
2015 Robins HI, Zhang P, Gilbert M, Chakravarti A, deGroot J, Grimm S, Wang F, Lieberman F, Krauze A, Sharma A, Mohile N, Kee A, Colman H, Cavaliere R, Kesari S, et al. Atct-27Nrg Oncology/Rtog 0929: A Randomized Phase I/Ii Study Of Abt-888In Combination With Temozolomide In Recurrent Temozolomide Resistant Glioblastoma Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov206.27  0.307
2015 Piccioni D, Juarez T, Brown B, Rose L, Allgood V, Kesari S. Atct-18Phase Ii Study Of Mipsagargin (G-202), A Psma-Activated Prodrug Targeting The Tumor Endothelium, In Adult Patients With Recurrent Or Progressive Glioblastoma Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov206.18  0.416
2015 Kesari S, Ram Z. Atnt-19Tumor Treating Fields With Chemotherapy Compared To Chemotherapy Alone In Glioblastoma Patients At First Recurrence: A Post-Hoc Analysis Of The Ef-14 Trial. Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov205.19  0.37
2015 Juarez T, Piccioni D, Nguyen A, Brown B, Rose L, Pu M, Messer K, Kesari S. Atnt-13A Phase I Dose Escalation And Central Nervous System (Cns) Pharmacokinetic Study Of Dexanabinol In Patients With Brain Cancer Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov205.13  0.341
2015 Mukthavaram R, Jiang P, Nomura N, Pingle S, Butters J, Butters B, Kesari S. Atps-64Preclinical Studies Using Nativis Voyager Rfe System, A Novel Non-Invasive, Low Energy, Non-Thermal, Non-Ionizing Radiofrequency Energy (Rfe) Device In Glioblastoma Mouse Models Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov204.64  0.324
2014 Mrugala MM, Engelhard HH, Butowski N, Tran DD, Kew Y, Cavaliere R, Villano J, Bota D, Kesari S, Rudnick J, Sumrall A, Zhu JJ, Wong ET. 415OALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA - NOVOTTF-100A SYSTEM: UPDATED OUTCOMES AND TOXICITY BASED ON THE ANALYSIS OF PATIENT REGISTRY DATA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv137. PMID 28170762 DOI: 10.1093/Annonc/Mdu330.2  0.328
2014 van Vugt VA, Piccioni DE, Brown BD, Brown T, Saria MG, Juarez T, Kesari S. Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. Cns Oncology. 3: 257-65. PMID 25286037 DOI: 10.2217/Cns.14.29  0.358
2014 White NS, McDonald C, McDonald CR, Farid N, Kuperman J, Karow D, Schenker-Ahmed NM, Bartsch H, Rakow-Penner R, Holland D, Shabaik A, Bjørnerud A, Hope T, Hattangadi-Gluth J, Liss M, ... ... Kesari S, et al. Diffusion-weighted imaging in cancer: physical foundations and applications of restriction spectrum imaging. Cancer Research. 74: 4638-52. PMID 25183788 DOI: 10.1158/0008-5472.Can-13-3534  0.313
2014 Farid N, Almeida-Freitas DB, White NS, McDonald CR, Kuperman JM, Almutairi AA, Muller KA, VandenBerg SR, Kesari S, Dale AM. Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria). Journal of Neuro-Oncology. 120: 539-46. PMID 25135423 DOI: 10.1007/S11060-014-1583-2  0.37
2014 Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, ... Kesari S, et al. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. Journal of Neuro-Oncology. 119: 361-8. PMID 24942463 DOI: 10.1007/S11060-014-1486-2  0.399
2014 Pingle SC, Sultana Z, Pastorino S, Jiang P, Mukthavaram R, Chao Y, Bharati IS, Nomura N, Makale M, Abbasi T, Kapoor S, Kumar A, Usmani S, Agrawal A, Vali S, ... Kesari S, et al. In silico modeling predicts drug sensitivity of patient-derived cancer cells. Journal of Translational Medicine. 12: 128. PMID 24884660 DOI: 10.1186/1479-5876-12-128  0.305
2014 Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M, Piccioni D, Juarez T, Pingle SC, Makale M, Kesari S. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell International. 14: 26. PMID 24645697 DOI: 10.1186/1475-2867-14-26  0.357
2014 Muh CR, Joshi S, Singh AR, Kesari S, Durden DL, Makale MT. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. Journal of Neuro-Oncology. 116: 89-97. PMID 24162827 DOI: 10.1007/S11060-013-1283-3  0.41
2014 Pastorino S, Langley EJ, Chao Y, Jiang P, Mukthavaram R, Pingle SC, Kim PS, Singh S, Kesari S. Mechanisms of resistance to PDGFR inhibition in glioblastoma. Journal of Clinical Oncology. 32: e13030-e13030. DOI: 10.1200/Jco.2014.32.15_Suppl.E13030  0.355
2014 Robbins JM, Huang TT, Jolly DJ, Kasahara N, Aghi MK, Vogelbaum MA, Cloughesy TF, Chang SM, Kesari S, Mikkelsen T, Kalkanis SN, Landolfi JC, Elder JB, Chiocca EA, Gruber HE, et al. Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high-grade glioma. Journal of Clinical Oncology. 32: 3078-3078. DOI: 10.1200/Jco.2014.32.15_Suppl.3078  0.396
2014 Lin NU, Gabrail NY, Sarantopoulos J, Schwartzberg LS, Kesari S, Bates SE, Anders CK, Elias AD, Castaigne J, Iordanova V, Lawrence B, Kurzrock R. Evaluation of CNS and peripheral antitumor activity of ANG1005 in patients with brain metastases from breast tumors and other advanced solid tumors. Journal of Clinical Oncology. 32: 2523-2523. DOI: 10.1200/Jco.2014.32.15_Suppl.2523  0.388
2014 Pingle SC, Sultana Z, Jiang P, Mukthavaram R, Chao Y, Abbasi T, Kapoor S, Kumar A, Usmani S, Agrawal A, Vali S, Kesari S. Predicting GBM response to targeted therapeutics using simulation with ex vivo validations. Journal of Clinical Oncology. 32: 2041-2041. DOI: 10.1200/Jco.2014.32.15_Suppl.2041  0.316
2014 Kesari S, Xiu J, Spetzer DB, Ghazalpour A, Gatalica Z, Sanai N. Results of comprehensive molecular profiling of gliomas and the potential therapeutic implications. Journal of Clinical Oncology. 32: 2013-2013. DOI: 10.1200/Jco.2014.32.15_Suppl.2013  0.36
2014 Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu J, Glantz MJ, Peereboom DM, Markert J, LaRocca RV, O'Rourke D, Fink KL, Kim LJ, Gruber ML, ... ... Kesari S, et al. A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. Journal of Clinical Oncology. 32: 2005-2005. DOI: 10.1200/Jco.2014.32.15_Suppl.2005  0.356
2014 Lee EQ, Muzikansky A, Kesari S, Wong ET, Fadul CE, Reardon DA, Norden AD, Nayak L, Rinne ML, Alexander BM, Arvold ND, Doherty LM, LaFrankie DC, Pulverenti J, Smith KH, et al. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Journal of Clinical Oncology. 32: 2004-2004. DOI: 10.1200/Jco.2014.32.15_Suppl.2004  0.302
2014 Pingle SC, Pastorino S, Muktharavam R, Jiang P, Chao Y, Abbasi T, Vali S, Kesari S. Abstract 5339: Deterministic in silico modeling predicts sensitivity of glioblastoma to targeted therapy Cancer Research. 74: 5339-5339. DOI: 10.1158/1538-7445.Am2014-5339  0.362
2014 Pastorino S, Pingle SC, Langley E, Kim P, Juarez T, Jiang P, Tucker C, Yang T, Saria M, Singh S, Kesari S. Abstract 4652: Cerebrospinal fluid pharmacokinetics and pharmacodynamics following high-dose erlotinib treatment in brain cancer patients Cancer Research. 74: 4652-4652. DOI: 10.1158/1538-7445.Am2014-4652  0.363
2014 Jiang P, Mukthavavam R, Nomura N, Pingle SC, Kesari S. Abstract 1628: Direct anti-cancer effects of zoledronic acid on human cancer cell Cancer Research. 74: 1628-1628. DOI: 10.1158/1538-7445.Am2014-1628  0.329
2014 Stupp R, Wong E, Scott C, Taillibert S, Kanner A, Kesari S, Ram Z. NT-40Interim Analysis of the EF-14 Trial: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou265.40  0.334
2014 Cloughesy TF, Kesari S, Kalkanis S, Mikkelsen T, Landolfi J, Elder JB, Liau LM, Chen CC, Bloomfield S, Piccioni D, Chiocca EA, Foltz G, Robbins JM, Ostertag D, Jolly DJ, et al. IT-05 * ADMINISTRATION OF TOCA 511 TO SUBJECTS WITH RECURRENT HGG UNDERGOING REPEAT RESECTION Neuro-Oncology. 16: v110-v111. DOI: 10.1093/Neuonc/Nou258.4  0.406
2014 Wen P, Reardon D, Phuphanich S, Aiken R, Landolfi J, Curry W, Zhu J, Glantz M, Peereboom D, Markert J, Larocca R, O'Rourke D, Fink K, Kim L, Gruber M, ... ... Kesari S, et al. At-60A Randomized Double Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell (Dc) Vaccine Ict-107 Following Standard Treatment In Newly Diagnosed Patients With Gbm Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.59  0.324
2014 Aghi M, Vogelbaum MA, Kesari S, Chen CC, Liau LM, Piccioni D, Portnow J, Chang S, Robbins JM, Boyce T, Huang TT, Pertschuk D, Ostertag D, Cloughesy TF. AT-02 * INTRATUMORAL DELIVERY OF THE RETROVIRAL REPLICATING VECTOR (RRV) TOCA 511 IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA: INTERIM REPORT OF PHASE 1 STUDY (NCT 01156584) Neuro-Oncology. 16: v8-v8. DOI: 10.1093/Neuonc/Nou237.2  0.356
2014 Kesari S, Tsigelny IF, Mukthavaram R, Kouznetsova VL, Chao Y, Pastorino S, Jiang P, Pingle SC, Wrasidlo W, Makale M. DEVELOPMENT OF NOVEL SMALL MOLECULES THAT TARGET GLIOBLASTOMA STEM CELLS Neuro-Oncology. 16: iii17-iii17. DOI: 10.1093/Neuonc/Nou206.61  0.303
2013 Hu J, Kesari S. Strategies for overcoming the blood-brain barrier for the treatment of brain metastases. Cns Oncology. 2: 87-98. PMID 25054359 DOI: 10.2217/Cns.12.37  0.344
2013 Mukthavaram R, Jiang P, Saklecha R, Simberg D, Bharati IS, Nomura N, Chao Y, Pastorino S, Pingle SC, Fogal V, Wrasidlo W, Makale M, Kesari S. High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile. International Journal of Nanomedicine. 8: 3991-4006. PMID 24174874 DOI: 10.2147/Ijn.S51949  0.347
2013 Piccioni DE, Kesari S. Clinical trials of viral therapy for malignant gliomas. Expert Review of Anticancer Therapy. 13: 1297-305. PMID 24138481 DOI: 10.1586/14737140.2013.851160  0.329
2013 Farid N, Almeida-Freitas DB, White NS, McDonald CR, Muller KA, Vandenberg SR, Kesari S, Dale AM. Restriction-Spectrum Imaging of Bevacizumab-Related Necrosis in a Patient with GBM. Frontiers in Oncology. 3: 258. PMID 24137566 DOI: 10.3389/Fonc.2013.00258  0.341
2013 Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. Journal of Neuro-Oncology. 115: 71-7. PMID 23828279 DOI: 10.1007/S11060-013-1196-1  0.358
2013 Davis DL, Kesari S, Soskolne CL, Miller AB, Stein Y. Swedish review strengthens grounds for concluding that radiation from cellular and cordless phones is a probable human carcinogen. Pathophysiology : the Official Journal of the International Society For Pathophysiology / Isp. 20: 123-9. PMID 23664410 DOI: 10.1016/J.Pathophys.2013.03.001  0.308
2013 Shi G, Cui W, Benchimol M, Liu YT, Mattrey RF, Mukthavaram R, Kesari S, Esener SC, Simberg D. Isolation of rare tumor cells from blood cells with buoyant immuno-microbubbles. Plos One. 8: e58017. PMID 23516425 DOI: 10.1371/Journal.Pone.0058017  0.346
2013 Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, ... ... Kesari S, et al. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. Journal of Neurosurgery. 118: 1183-7. PMID 23451905 DOI: 10.3171/2013.1.Jns12397  0.376
2013 Yost SE, Pastorino S, Rozenzhak S, Smith EN, Chao YS, Jiang P, Kesari S, Frazer KA, Harismendy O. High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models. Plos One. 8: e56185. PMID 23441165 DOI: 10.1371/Journal.Pone.0056185  0.381
2013 McDonald CR, White NS, Farid N, Lai G, Kuperman JM, Bartsch H, Hagler DJ, Kesari S, Carter BS, Chen CC, Dale AM. Recovery of white matter tracts in regions of peritumoral FLAIR hyperintensity with use of restriction spectrum imaging. Ajnr. American Journal of Neuroradiology. 34: 1157-63. PMID 23275591 DOI: 10.3174/Ajnr.A3372  0.304
2013 White NS, McDonald CR, Farid N, Kuperman JM, Kesari S, Dale AM. Improved conspicuity and delineation of high-grade primary and metastatic brain tumors using "restriction spectrum imaging": quantitative comparison with high B-value DWI and ADC. Ajnr. American Journal of Neuroradiology. 34: 958-64, S1. PMID 23139079 DOI: 10.3174/Ajnr.A3327  0.35
2013 Saria MG, Corle C, Rush T, Kesari S. Improved survival of patients with glioblastoma at NCI-designated clinical cancer centers. Journal of Clinical Oncology. 31: 122-122. DOI: 10.1200/Jco.2013.31.31_Suppl.122  0.36
2013 Carpentier AF, Brandes AA, Kesari S, Sepúlveda JM, Wheeler H, Chinot OL, Cher L, Steinbach JP, Specenier PM, Cleverly A, Tomlin I, Desaiah D, Lahn MMF, Wick W. Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression. Journal of Clinical Oncology. 31: 2061-2061. DOI: 10.1200/Jco.2013.31.15_Suppl.2061  0.316
2013 Jiang P, Mukthavavam R, Chao Y, Nomura N, Fogal V, Pastorino S, Summit I, Kesari S. Abstract 1856: Preclinical study for statins as anticancer drug. Cancer Research. 73: 1856-1856. DOI: 10.1158/1538-7445.Am2013-1856  0.342
2013 Lin NU, Schwartzberg L, Kesari S, Elias A, Anders C, Raizer J, Kozloff M, Amiri-Kordestani L. Abstract B76: A phase II study of ANG1005, a novel, brain-penetrant taxane derivative, in breast cancer patients with brain metastases. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B76  0.356
2012 Elbabaa SK, Gokden M, Crawford JR, Kesari S, Saad AG. Radiation-associated meningiomas in children: clinical, pathological, and cytogenetic characteristics with a critical review of the literature. Journal of Neurosurgery. Pediatrics. 10: 281-90. PMID 22900483 DOI: 10.3171/2012.7.Peds1251  0.314
2012 Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2307-13. PMID 22547604 DOI: 10.1200/Jco.2011.39.1540  0.328
2012 Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, Kim RY, Saria MG, Pastorino S, Kesari S, Krichevsky AM. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro-Oncology. 14: 689-700. PMID 22492962 DOI: 10.1093/Neuonc/Nos074  0.354
2012 Ulmer S, Spalek K, Nabavi A, Schultka S, Mehdorn HM, Kesari S, Dörner L. Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma. Neuro-Oncology. 14: 482-90. PMID 22319220 DOI: 10.1093/Neuonc/Nos003  0.31
2012 Cai P, Mahta A, Kim RY, Kesari S. Paraganglioma with intracranial metastasis: a case report and review of the literature. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 33: 1183-4. PMID 22187335 DOI: 10.1007/S10072-011-0879-7  0.316
2012 Pan H, Alksne J, Mundt AJ, Murphy KT, Cornell M, Kesari S, Lawson JD. Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study. Medical Oncology (Northwood, London, England). 29: 2040-5. PMID 22108847 DOI: 10.1007/S12032-011-0116-5  0.354
2012 Grewal J, Saria MG, Kesari S. Novel approaches to treating leptomeningeal metastases. Journal of Neuro-Oncology. 106: 225-34. PMID 21874597 DOI: 10.1007/S11060-011-0686-2  0.346
2012 Corle C, Makale M, Kesari S. Cell phones and glioma risk: a review of the evidence. Journal of Neuro-Oncology. 106: 1-13. PMID 21853424 DOI: 10.1007/S11060-011-0663-9  0.392
2012 Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S. Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. Journal of Neuro-Oncology. 106: 427-9. PMID 21833801 DOI: 10.1007/S11060-011-0675-5  0.342
2012 Mahta A, Kim RY, Kesari S. Fourth ventricular choroid plexus papilloma. Medical Oncology (Northwood, London, England). 29: 1285-6. PMID 21630054 DOI: 10.1007/S12032-011-9994-9  0.352
2012 Hu XQ, Imitola J, Kim RY, Mahta A, Kesari S. Brain metastasis from ovarian cancer: case report and review of the literature. Medical Oncology (Northwood, London, England). 29: 1250-2. PMID 21380785 DOI: 10.1007/S12032-011-9876-1  0.314
2012 Hammond S, Drappatz J, Lee E, Muzikansky A, Weiss S, Kesari S, Wong E, Fadul C, Norden A, Beroukhim R, Alexander B, Ruland S, Ciampa A, Lafrankie D, Doherty L, et al. Interim Analysis of a Randomized Placebo-Controlled Pilot Trial of Armodafinil for Fatigue in Patients with Malignant Gliomas Undergoing Radiotherapy with or without Standard Chemotherapy Treatment (P07.104) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P07.104  0.319
2012 Hawkins ES, Aiken R, Chandler J, Fink KL, Glantz MJ, Grewal J, Gruber ML, Kesari S, Landolfi JC, LaRocca RV, Lesser GJ, Markert J, Mayer TM, O'Rourke D, Peereboom DM, et al. A randomized, double‑blind, controlled phase IIb study of the safety and efficacy of ICT‑107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps2107  0.387
2012 Kesari S, Taillibert S, Kanner A, Weinberg U. Phase III trial of tumor-treating fields (TTFields) together with temozolomide compared with temozolomide (TMZ) alone in patients with newly diagnosed glioblastoma multiforme (NCT00916409). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps2106  0.385
2012 Pertschuk D, Cloughesy TF, Chang SM, Aghi MK, Vogelbaum MA, Liau LM, Shafa BB, Yong WH, Chen C, Kesari S, Ibanez CE, Perez OD, Robbins JM, Jolly DJ, Gruber HE. Ascending dose trials of the safety and tolerability of Toca 511, a retroviral replicating vector encoding cytosine deaminase, in patients with recurrent high-grade glioma. Journal of Clinical Oncology. 30: 2101-2101. DOI: 10.1200/Jco.2012.30.15_Suppl.2101  0.383
2012 Scott BJ, Feely H, Brown T, Vugt VV, Kim R, Fanta PT, Bazhenova L, Kesari S. Concurrent intrathecal methotrexate and liposomal cytarabine for the treatment of leptomeningeal metastasis from solid tumors. Journal of Clinical Oncology. 30: 2052-2052. DOI: 10.1200/Jco.2012.30.15_Suppl.2052  0.399
2012 Verma IM, Soda Y, Friedmann-Morvinski D, Pastorino S, Kesari S. Abstract SY41-01: Tumor-endothelial transdifferentiation Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy41-01  0.374
2012 Pastorino S, Chao Y, Gallagher M, Mukthavaram R, Fogal V, Bharati I, Makale M, Jiang P, Kesari S. Abstract 5203: Lineage-specific mechanisms regulating PDGFRα oncogenic activity in glioblastoma Cancer Research. 72: 5203-5203. DOI: 10.1158/1538-7445.Am2012-5203  0.416
2012 Jiang P, Mukthavaram R, Summitt I, Chao Y, Gallagher M, Kim R, Pastorino S, Kesari S. Abstract 3680: Drug screening for glioblastoma patients Cancer Research. 72: 3680-3680. DOI: 10.1158/1538-7445.Am2012-3680  0.321
2012 Fogal V, Chao YS, Pastorino S, Wang L, Jian P, Mukthavaram R, Gallagher M, Summitt IB, Kesari S. Abstract 1115: p32 is a downstream effector of c-Myc induced glutamine addiction Cancer Research. 72: 1115-1115. DOI: 10.1158/1538-7445.Am2012-1115  0.326
2012 Lin N, Schwartzberg L, Kesari S, Yardley D, Verma S, Anders C, Shih T, Shen Y, Miller K. Abstract P3-12-04: A phase 2, multi-center, open label study evaluating the efficacy and safety of GRN1005 alone or in combination with trastuzumab in patients with brain metastases from breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P3-12-04  0.354
2011 Grewal J, Saria M, Grewal HK, Kesari S. Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome. Clinical Investigation. 1: 1391-1402. PMID 22396850 DOI: 10.4155/Cli.11.115  0.326
2011 Kesari S, Advani SJ, Lawson JD, Kahle KT, Ng K, Carter B, Chen CC. DNA damage response and repair: insights into strategies for radiation sensitization of gliomas. Future Oncology (London, England). 7: 1335-46. PMID 22044206 DOI: 10.2217/Fon.11.111  0.319
2011 Ziegler DS, Keating J, Kesari S, Fast EM, Zawel L, Ramakrishna N, Barnes J, Kieran MW, Veldhuijzen van Zanten SE, Kung AL. A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. Neuro-Oncology. 13: 820-9. PMID 21724651 DOI: 10.1093/Neuonc/Nor066  0.393
2011 Lin N, Dunn IF, Glantz M, Allison DL, Jensen R, Johnson MD, Friedlander RM, Kesari S. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. Journal of Neurosurgery. 115: 730-6. PMID 21721878 DOI: 10.3171/2011.5.Jns101768  0.368
2011 Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Review of Clinical Pharmacology. 4: 233-42. PMID 21666852 DOI: 10.1586/Ecp.11.1  0.421
2011 Hu A, Xu Z, Kim RY, Nguyen A, Lee JW, Kesari S. Seizure control: A secondary benefit of chemotherapeutic temozolomide in brain cancer patients Epilepsy Research. 95: 270-272. PMID 21549564 DOI: 10.1016/J.Eplepsyres.2011.03.018  0.349
2011 Agnihotri S, Wolf A, Munoz DM, Smith CJ, Gajadhar A, Restrepo A, Clarke ID, Fuller GN, Kesari S, Dirks PB, McGlade CJ, Stanford WL, Aldape K, Mischel PS, Hawkins C, et al. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. The Journal of Experimental Medicine. 208: 689-702. PMID 21464220 DOI: 10.1084/Jem.20102099  0.36
2011 Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, Pastorino S, Yang M, Hoffman RM, Kesari S, Verma IM. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 4274-80. PMID 21262804 DOI: 10.1073/Pnas.1016030108  0.359
2011 Chaponis D, Barnes JW, Dellagatta JL, Kesari S, Fast E, Sauvageot C, Panagrahy D, Greene ER, Ramakrishna N, Wen PY, Kung AL, Stiles C, Kieran MW. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas Journal of Neuro-Oncology. 104: 179-189. PMID 21246394 DOI: 10.1007/S11060-010-0502-4  0.372
2011 Wong K, Young GS, Makale M, Hu X, Yildirim N, Cui K, Wong ST, Kesari S. Characterization of a human tumorsphere glioma orthotopic model using magnetic resonance imaging. Journal of Neuro-Oncology. 104: 473-81. PMID 21240539 DOI: 10.1007/S11060-010-0517-X  0.332
2011 Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, ... Kesari S, et al. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. International Journal of Radiation Oncology, Biology, Physics. 81: 1422-7. PMID 20934264 DOI: 10.1016/J.Ijrobp.2010.07.1997  0.324
2010 Chen J, Kesari S, Rooney C, Strack PR, Chen J, Shen H, Wu L, Griffin JD. Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes & Cancer. 1: 822-35. PMID 21127729 DOI: 10.1177/1947601910383564  0.315
2010 Dietrich J, Diamond EL, Kesari S. Glioma stem cell signaling: Therapeutic opportunities and challenges Expert Review of Anticancer Therapy. 10: 709-722. PMID 20470003 DOI: 10.1586/Era.09.190  0.36
2010 Lee JW, Wen PY, Hurwitz S, Black P, Kesari S, Drappatz J, Golby AJ, Wells WM, Warfield SK, Kikinis R, Bromfield EB. Morphological characteristics of brain tumors causing seizures. Archives of Neurology. 67: 336-42. PMID 20212231 DOI: 10.1001/Archneurol.2010.2  0.332
2010 Zeng Q, Yang Z, Gao YJ, Yuan H, Cui K, Shi Y, Wang H, Huang X, Wong ST, Wang Y, Kesari S, Ji RR, Xu X. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study. European Journal of Cancer (Oxford, England : 1990). 46: 1132-43. PMID 20156674 DOI: 10.1016/J.Ejca.2010.01.014  0.334
2010 Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. International Journal of Radiation Oncology, Biology, Physics. 78: 85-90. PMID 20137866 DOI: 10.1016/J.Ijrobp.2009.07.1741  0.326
2009 Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, Kesari S, Berger JR, Simpson DM, Prosperi M, De Luca A, Koralnik IJ. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology. 73: 1551-8. PMID 19901246 DOI: 10.1212/Wnl.0B013E3181C0D4A1  0.302
2009 Glantz M, Kesari S, Recht L, Fleischhack G, Van Horn A. Understanding the origins of gliomas and developing novel therapies: cerebrospinal fluid and subventricular zone interplay. Seminars in Oncology. 36: S17-24. PMID 19660679 DOI: 10.1053/J.Seminoncol.2009.05.003  0.412
2009 Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3518-25. PMID 19528374 DOI: 10.1200/Jco.2008.18.3087  0.343
2009 Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Research. 69: 3472-81. PMID 19351838 DOI: 10.1158/0008-5472.Can-08-3886  0.384
2009 Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, LaFrankie D, Ciampa A, Kesari S, Wen PY. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab Neuro-Oncology. 11: 550-555. PMID 19332770 DOI: 10.1215/15228517-2009-006  0.384
2009 Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-Oncology. 11: 853-60. PMID 19293394 DOI: 10.1215/15228517-2009-010  0.386
2009 Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 330-7. PMID 19118062 DOI: 10.1158/1078-0432.Ccr-08-0888  0.367
2009 Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma Journal of Neuro-Oncology. 92: 149-155. PMID 19043778 DOI: 10.1007/S11060-008-9745-8  0.355
2009 Ulmer S, Liess C, Kesari S, Otto N, Straube T, Jansen O. Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma. Journal of Neuro-Oncology. 91: 213-20. PMID 18807224 DOI: 10.1007/S11060-008-9701-7  0.341
2009 Norden AD, Drappatz J, Ciampa AS, Doherty L, Lafrankie DC, Kesari S, Wen PY. Colon perforation during antiangiogenic therapy for malignant glioma Neuro-Oncology. 11: 92-95. PMID 18757774 DOI: 10.1215/15228517-2008-071  0.334
2009 Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW, Wen PY. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro-Oncology. 11: 109-21. PMID 18682579 DOI: 10.1215/15228517-2008-060  0.359
2009 Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics. 73: 222-7. PMID 18513880 DOI: 10.1016/J.Ijrobp.2008.03.046  0.354
2009 Zhao H, Zhu J, Cui K, Xu X, O'Brien M, Wong KK, Kesari S, Xia W, Wong STC. Bioluminescence imaging reveals inhibition of tumor cell proliferation by Alzheimer's amyloid β protein Cancer Cell International. 9. DOI: 10.1186/1475-2867-9-15  0.324
2009 Dietrich J, Kesari S. Effect of cancer treatment on neural stem and progenitor cells Cancer Treatment and Research. 150: 81-95. DOI: 10.1007/B109924_6  0.338
2008 Bracht LK, Wen P, Meyerhardt JA, Kulke MH, Hornick JL, Redston M, LaFrankie DC, Black PM, Kesari S, Norden A, Drappatz J. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4843-4. PMID 18779600 DOI: 10.1200/Jco.2008.18.1776  0.32
2008 Wen PY, Kesari S. Malignant Gliomas in Adults The New England Journal of Medicine. 359: 492-507. PMID 18669428 DOI: 10.1056/Nejmra0708126  0.3
2008 Dietrich J, Imitola J, Kesari S. Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas. Nature Clinical Practice. Oncology. 5: 393-404. PMID 18521117 DOI: 10.1038/Ncponc1132  0.339
2008 Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-Oncology. 10: 300-8. PMID 18403492 DOI: 10.1215/15228517-2008-005  0.346
2008 Grewal J, Kesari S. Breast cancer surface receptors predict risk for developing brain metastasis and subsequent prognosis Breast Cancer Research. 10: 104-104. PMID 18373884 DOI: 10.1186/Bcr1868  0.308
2008 Kesari S, Kim RS, Markos V, Drappatz J, Wen PY, Pruitt AA. Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases. Journal of Neuro-Oncology. 88: 175-83. PMID 18365144 DOI: 10.1007/S11060-008-9545-1  0.36
2008 Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 70: 779-87. PMID 18316689 DOI: 10.1212/01.Wnl.0000304121.57857.38  0.41
2008 Akar S, Drappatz J, Hsu L, Blinder RA, Black PM, Kesari S. Hypertrophic olivary degeneration after resection of a cerebellar tumor Journal of Neuro-Oncology. 87: 341-345. PMID 18217209 DOI: 10.1007/S11060-008-9523-7  0.338
2007 Evans CL, Xu X, Kesari S, Xie XS, Wong ST, Young GS. Chemically-selective imaging of brain structures with CARS microscopy. Optics Express. 15: 12076-87. PMID 19547572 DOI: 10.1364/Oe.15.012076  0.311
2007 Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical Management of Brain Tumor Patients Neurologic Clinics. 25: 1035-1071. PMID 17964025 DOI: 10.1016/J.Ncl.2007.07.015  0.339
2007 Sauvageot CM, Kesari S, Stiles CD. Molecular pathogenesis of adult brain tumors and the role of stem cells. Neurologic Clinics. 25: 891-924, vii. PMID 17964020 DOI: 10.1016/J.Ncl.2007.07.014  0.382
2007 Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-Oncology. 9: 354-63. PMID 17452651 DOI: 10.1215/15228517-2007-006  0.376
2007 Kesari S, Jackson-Grusby L, Stiles CD. "Smad"eningly erratic: target gene methylation determines whether TGFbeta promotes or suppresses malignant glioma. Developmental Cell. 12: 324-5. PMID 17336898 DOI: 10.1016/J.Devcel.2007.02.008  0.34
2007 Monje ML, Ramakrishna NR, Young G, Drappatz J, Doherty LM, Wen PY, Kesari S. Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. Journal of Neuro-Oncology. 84: 179-83. PMID 17332945 DOI: 10.1007/S11060-007-9354-Y  0.344
2007 Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, Depinho RA, Anderson DJ, Stiles CD, Rowitch DH. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 53: 503-17. PMID 17296553 DOI: 10.1016/J.Neuron.2007.01.009  0.31
2007 Narin O, Drappatz J, Doherty LM, Wen PY, Kesari S. Cerebrospinal fluid spread of anaplastic glioma. Journal of Clinical Oncology. 25: 596-597. PMID 17290068 DOI: 10.1200/Jco.2006.09.3096  0.389
2007 Gerin F, Baloglu O, Morgan JA, Kesari S. Central nervous system metastases from imatinib mesylate resistant gastrointestinal stromal tumor. Journal of Neuro-Oncology. 82: 227-228. PMID 17106648 DOI: 10.1007/S11060-006-9277-Z  0.326
2006 Doherty L, Gigas DC, Kesari S, Drappatz J, Kim RS, Zimmerman J, Ostrowsky L, Wen PY. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology. 67: 156-158. PMID 16832099 DOI: 10.1212/01.Wnl.0000223844.77636.29  0.37
2006 Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L. Medical management of patients with brain tumors Journal of Neuro-Oncology. 80: 313-332. PMID 16807780 DOI: 10.1007/S11060-006-9193-2  0.346
2006 Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Current Oncology Reports. 8: 58-70. PMID 16464405 DOI: 10.1007/S11912-006-0011-Y  0.346
2006 Shah GD, Kesari S, Xu R, Batchelor TT, O'Neill AM, Hochberg FH, Levy B, Bradshaw J, Wen PY. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro-Oncology. 8: 38-46. PMID 16443946 DOI: 10.1215/S1522851705000529  0.366
2006 Rosovsky RP, Wen P, Kesari S, Cott EMV, Kuter DJ. The Identification of Hypercoagulable Markers in Patients with Malignant Gliomas and Venous Thromboembolism. Blood. 108: 4097-4097. DOI: 10.1182/Blood.V108.11.4097.4097  0.378
2005 Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Current Neurology and Neuroscience Reports. 5: 186-97. PMID 15865884 DOI: 10.1007/S11910-005-0046-8  0.346
2004 Mrugala MM, Kesari S, Ramakrishna N, Wen PY. Therapy for recurrent malignant glioma in adults. Expert Review of Anticancer Therapy. 4: 759-782. PMID 15485312 DOI: 10.1586/14737140.4.5.759  0.385
Low-probability matches (unlikely to be authored by this person)
2012 Mahta A, Borys E, Kanakamedala MR, Kesari S. Radiation induced myelopathy in a patient with tongue cancer: a case report. Acta Oncologica (Stockholm, Sweden). 51: 409-11. PMID 22060135 DOI: 10.3109/0284186X.2011.631578  0.3
2015 Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, et al. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. Journal of Neuro-Oncology. PMID 26508094 DOI: 10.1007/S11060-015-1966-Z  0.3
2015 Mukthavaram R, Jiang P, Nomura N, Pingle SC, Butters J, Butters BM, Kesari S. Preclinical studies using Nativis Voyager RFE System, a novel non-invasive, low energy, non-thermal, non-ionizing radiofrequency energy (RFE) device in glioblastoma mouse models. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E13050  0.299
2018 Tran D, Kesari S, Bota DA. Qolp-15. Safety And Adverse Event Profile Of Tumor Treating Fields In Anaplastic Glioma A Post-Marketing Surveillance Analysis Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.901  0.299
2006 Wen PY, Kesari S, Drappatz J. Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment Expert Review of Anticancer Therapy. 6: 733-754. PMID 16759164 DOI: 10.1586/14737140.6.5.733  0.298
2015 Nozawa A, Rivandi AH, Kanematsu M, Hoshi H, Piccioni D, Kesari S, Hoh CK. Glucose-corrected standardized uptake value in the differentiation of high-grade glioma versus post-treatment changes. Nuclear Medicine Communications. 36: 573-81. PMID 25714806 DOI: 10.1097/Mnm.0000000000000288  0.297
2016 Ferguson SD, Xiu J, Weathers SP, Zhou S, Kesari S, Weiss SE, Verhaak RG, Hohl RJ, Barger GR, Reddy SK, Heimberger AB. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. PMID 27579614 DOI: 10.18632/Oncotarget.11617  0.297
2008 Ziegler DS, Wright RD, Kesari S, Lemieux ME, Tran MA, Jain M, Zawel L, Kung AL. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. The Journal of Clinical Investigation. 118: 3109-22. PMID 18677408 DOI: 10.1172/Jci34120  0.297
2015 Tsigelny IF, Kouznetsova VL, Jiang P, Pingle SC, Kesari S. Hierarchical control of coherent gene clusters defines the molecular mechanisms of glioblastoma. Molecular Biosystems. 11: 1012-28. PMID 25648506 DOI: 10.1039/C5Mb00007F  0.295
2012 Mahta A, Borys E, Kesari S. Cerebellar glioneuronal tumor: a case report and review of the literature. Medical Oncology (Northwood, London, England). 29: 2038-9. PMID 21993631 DOI: 10.1007/S12032-011-0078-7  0.294
2016 Aghi M, Vogelbaum M, Kalkanis S, Bota D, Carter B, Chen C, Elder B, Engh J, Goldlust S, Kaptain G, Kesari S, Landolfi J, Liau L, Mikkelsen T, Piccioni D, et al. ATIM-05. COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL Neuro-Oncology. 18: vi18-vi18. DOI: 10.1093/Neuonc/Now212.070  0.294
2006 Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jänne PA, Johnson BE. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4517-20. PMID 16983123 DOI: 10.1200/Jco.2006.06.6126  0.294
2018 Mukherjee A, Waters AK, Babic I, Nurmemmedov E, Glassy MC, Kesari S, Yenugonda VM. Antibody drug conjugates: Progress, pitfalls, and promises. Human Antibodies. PMID 30223393 DOI: 10.3233/Hab-180348  0.294
2013 Kothari PD, White NS, Farid N, Chung R, Kuperman JM, Girard HM, Shankaranarayanan A, Kesari S, McDonald CR, Dale AM. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab. Ajnr. American Journal of Neuroradiology. 34: 1752-7. PMID 23578667 DOI: 10.3174/Ajnr.A3506  0.294
2008 Lee JW, Bromfield E, Kesari S. Emesis responsive to levetiracetam Journal of Neurology, Neurosurgery, and Psychiatry. 79: 847-849. PMID 18559467 DOI: 10.1136/Jnnp.2007.142117  0.293
2010 Schiff D, Reardon DA, Kesari S, Mikkelsen T, Groot JFD, Fichtel L, Coyle TE, Wong E, Eaton C, Silver B. Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM). Journal of Clinical Oncology. 28: 2011-2011. DOI: 10.1200/Jco.2010.28.15_Suppl.2011  0.292
2011 Yu-chang L, Kesari S, Bing L, Ya-suo D, Ming-zhi P. Individual management of recurrent intracranial aneurysms: the Wuxi experience. Cell Biochemistry and Biophysics. 61: 349-54. PMID 21706366 DOI: 10.1007/S12013-011-9217-1  0.292
2017 Rodvold JJ, Kesari S, Zanetti M. A community affair in the tumor microenvironment. Oncotarget. 8: 106173-106174. PMID 29290938 DOI: 10.18632/Oncotarget.22586  0.292
2016 Tsigelny IF, Kouznetsova VL, Lian N, Kesari S. Molecular mechanisms of OLIG2 transcription factor in brain cancer. Oncotarget. PMID 27447975 DOI: 10.18632/Oncotarget.10628  0.291
2010 Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, Kesari S, Inda MM, Wykosky J, Furnari F, Hoadley KA, Chin L, DePinho RA, Cavenee WK, et al. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. Plos One. 5: e10767. PMID 20532243 DOI: 10.1371/Journal.Pone.0010767  0.29
2018 Hu J, Kesari S. Search for More Effective Chemotherapeutic Regimens for Gliomas: Challenges and Hopes. Progress in Neurological Surgery. 31: 200-209. PMID 29393187 DOI: 10.1159/000467380  0.289
2010 Xia Z, Mehta BP, Ropper AH, Kesari S. Paraneoplastic limbic encephalitis presenting as a neurological emergency: a case report. Journal of Medical Case Reports. 4: 95. PMID 20334684 DOI: 10.1186/1752-1947-4-95  0.289
2017 Bota D, Desjardins A, Mason W, Kesari S, Magge R, Winograd B, Reich SD, Levin N, Trikha M. Actr-71. Full Enrollment Results From The Phase 1/2, Multicenter, Open-Label Study Of Marizomib (Mrz) ± Bevacizumab (Bev) In Recurrent Who Grade Iv Malignant Glioma (Glioblastoma, Rgbm) Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.058  0.286
2019 Carrillo J, Wagle N, Barkhoudarian G, Kelly D, Heng A, Gill J, Juarez T, Kesari S. Mngi-05. Combined Multimodal Treatment Regimen In Recurrent Meningiomas Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.587  0.286
2018 Sumrall A, Phuphanich S, Spetzler D, Gatalica Z, Xiu J, Provenzano A, Brenner AJ, Subramaniam D, Pandey M, Heimberger A, Kesari S, Korn WM, Mittal S. Rare-22. Frequent High Tumor Mutational Burden (Tmb) And Pd-L1 Expression In Primary Cns Lymphoma (Pcnsl) Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.996  0.285
2018 Grubman ME, Saria MG, Nguyen M, Trong J, Boucher N, Gill J, Heng A, Moses AA, Juarez T, Achrol A, O'Day S, Barkhoudarian G, Kelly DF, Kesari S. A comprehensive initiative to optimize accrual to neuro oncology clinical trials. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E18546  0.285
2011 Mahta A, Kim RY, Fanta PT, Lawson JD, Kesari S. Leptomeningeal Metastasis from Appendiceal Adenocarcinoma: Case Report and Literature Review. Journal of Gastrointestinal Cancer. PMID 21826409 DOI: 10.1007/S12029-011-9312-Y  0.283
2014 Jiang P, Mukthavaram R, Chao Y, Nomura N, Bharati IS, Fogal V, Pastorino S, Teng D, Cong X, Pingle SC, Kapoor S, Shetty K, Aggrawal A, Vali S, Abbasi T, ... ... Kesari S, et al. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. British Journal of Cancer. 111: 1562-71. PMID 25093497 DOI: 10.1038/Bjc.2014.431  0.283
2016 Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S. Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. Nature Reviews. Neurology. PMID 27982041 DOI: 10.1038/Nrneurol.2016.185  0.283
2011 Mahta A, Kim RY, Kesari S. Progressive multifocal leukoencephalopathy with wallerian degeneration. European Neurology. 66: 242. PMID 21967919 DOI: 10.1159/000331770  0.283
2008 Chen CC, Kennedy R, Kesari S, Kung A, DʼAndrea A. Proteasome Inhibition in High-grade Glioma Treatment Neurosurgery. 62: 1423. DOI: 10.1227/01.Neu.0000333525.31785.8F  0.283
2009 Kolesnikova TV, Kazarov AR, Lemieux ME, Lafleur MA, Kesari S, Kung AL, Hemler ME. Glioblastoma inhibition by cell surface immunoglobulin protein EWI-2, in vitro and in vivo. Neoplasia. 11: 77-86. PMID 19107234 DOI: 10.1593/Neo.81180  0.283
2014 Jiang P, Mukthavaram R, Mukthavavam R, Chao Y, Bharati IS, Fogal V, Pastorino S, Cong X, Nomura N, Gallagher M, Abbasi T, Vali S, Pingle SC, Makale M, Kesari S. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. Journal of Translational Medicine. 12: 13. PMID 24433351 DOI: 10.1186/1479-5876-12-13  0.282
2004 Wen PY, Kesari S. Malignant gliomas. Current Neurology and Neuroscience Reports. 4: 218-27. PMID 15102348 DOI: 10.1007/s11910-004-0042-4  0.28
2015 Tsigelny IF, Mukthavaram R, Kouznetsova VL, Chao Y, Babic I, Nurmemmedov E, Pastorino S, Jiang P, Calligaris D, Agar N, Scadeng M, Pingle SC, Wrasidlo W, Makale MT, Kesari S. Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma. Oncotarget. PMID 26517684 DOI: 10.18632/Oncotarget.5633  0.28
2015 Wang X, Zhang C, Yan X, Lan B, Wang J, Wei C, Cao X, Wang R, Yao J, Zhou T, Zhou M, Liu Q, Jiang B, Jiang P, Kesari S, et al. A novel bioavailable BH3 mimetic efficiently inhibits colon cancer via cascade effects of mitochondria. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26515494 DOI: 10.1158/1078-0432.Ccr-15-0732  0.279
2013 Liu X, Ide JL, Norton I, Marchionni MA, Ebling MC, Wang LY, Davis E, Sauvageot CM, Kesari S, Kellersberger KA, Easterling ML, Santagata S, Stuart DD, Alberta J, Agar JN, et al. Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging. Scientific Reports. 3: 2859. PMID 24091529 DOI: 10.1038/Srep02859  0.279
2017 Kesari S, Babic I, Mukthavaram R, Jiang P, Nomura N, Pingle SC, Juarez T, Yang J, Yenugonda V, Nurmemmedov E, Glassy MC. Pritumumab binding to glioma cells induces ADCC and inhibits tumor growth. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E14004  0.279
2013 Mahta A, Kim RY, Saad AG, Kesari S. 47-year-old man with left leg numbness. Brain Pathology (Zurich, Switzerland). 23: 223-4. PMID 23432649 DOI: 10.1111/Bpa.12033  0.278
2012 Mahta A, Qu Y, Nastic D, Sundstrom M, Kim RY, Saria M, Santagata S, Kesari S. Relapsing tumefactive lesion in an adult with medulloblastoma previously treated with chemoradiotherapy and stem cell transplant. Pathology Oncology Research : Por. 18: 539-43. PMID 21953324 DOI: 10.1007/S12253-011-9464-X  0.278
2008 Kesari S, Akar S, Saad A, Drappatz J, Koralnik IJ, DeAngelo DJ. Progressive Multifocal Leukoencephalopathy in a Patient With Relapsed Acute Myelogenous Leukemia Journal of Clinical Oncology. 26: 3804-3807. PMID 18669471 DOI: 10.1200/Jco.2008.17.3047  0.277
2012 Santagata S, Xu YM, Wijeratne EM, Kontnik R, Rooney C, Perley CC, Kwon H, Clardy J, Kesari S, Whitesell L, Lindquist S, Gunatilaka AA. Using the heat-shock response to discover anticancer compounds that target protein homeostasis. Acs Chemical Biology. 7: 340-9. PMID 22050377 DOI: 10.1021/Cb200353M  0.276
2019 Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, Markert J, LaRocca R, O'Rourke DM, Fink K, Kim L, ... ... Kesari S, et al. A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31320597 DOI: 10.1158/1078-0432.Ccr-19-0261  0.276
2016 Bota D, Desjardins A, Mason W, Fine H, Kesari S, Reich SD, Vashishtha A, Levin N, Trikha M. Actr-50. Marizomib (Mrz) With Bevacizumab (Bev) In Who Grade Iv Malignant Glioma (G4 Mg): Full Enrollment Results From The Phase 1, Multicenter, Open-Label Study Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.048  0.276
2008 Musunuru K, Kesari S. Paraneoplastic opsoclonus-myoclonus ataxia associated with non-small-cell lung carcinoma. Journal of Neuro-Oncology. 90: 213-216. PMID 18618225 DOI: 10.1007/S11060-008-9650-1  0.276
2020 Yenugonda VM, Waters A, Yadavalli S, Marzese D, Senugupta S, Nurmammadov E, Quan Y, Nomura N, Allnutt A, Kesari S. Abstract P5-05-12: Small molecule targeting regulated cell death pathways in treating triple negative breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P5-05-12  0.276
2018 Achrol A, Bexon M, Bankiewicz K, Brenner AJ, Butowski N, Kesari S, Merchant F, Merchant R, Randazzo D, Vogelbaum M, Zabek M, Sampson J. Atim-05. Intratumoral Delivery Of Mdna55, An Interleukin-4 Receptor Targeted Immunotherapy, By Mri-Guided Convective Delivery For The Treatment Of Recurrent Glioblastoma Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.002  0.276
2011 Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, Alberta JA, Kane MF, Theisen M, Ligon KL, Rowitch DH, Stiles CD. The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell. 19: 359-71. PMID 21397859 DOI: 10.1016/J.Ccr.2011.01.035  0.276
2015 Vogelbaum MA, Kesari S, Kalkanis SN, Mikkelsen T, Landolfi J, Elder JB, Chen CC, Robbins J, Ostertag D, Jolly DJ, Keller MR, Skillings J, Chu A, Cloughesy TF. SURG-09RESULTS OF A DOSE ESCALATION TRIAL OF TOCA 511 WITH TOCA FC IN RECURRENT HGG UNDERGOING REPEAT RESECTION Neuro-Oncology. 17: v216.1-v216. DOI: 10.1093/Neuonc/Nov235.09  0.274
2017 Grubman M, Saria MG, Gill J, Boucher N, Heng A, Johnson M, Juarez T, Kesari S. Hout-24. A Multipronged Approach To Improve Patient Access To Clinical Trials Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.454  0.274
2008 Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, Louis DN, Chin L, DePinho RA. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America. 105: 10703-8. PMID 18669646 DOI: 10.1073/Pnas.0712034105  0.274
2012 Moazzam AA, Drappatz J, Kim RY, Kesari S. Chronic lymphocytic leukemia with central nervous system involvement: report of two cases with a comprehensive literature review. Journal of Neuro-Oncology. 106: 185-200. PMID 21769650 DOI: 10.1007/S11060-011-0636-Z  0.273
2022 Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, Salacz ME, D'Andre S, Aiken RD, Moshel YA, Nam JY, ... ... Kesari S, et al. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. Jama Oncology. PMID 36394838 DOI: 10.1001/jamaoncol.2022.5370  0.272
2011 Qu Y, Davis JE, Chi J, Kesari S. 71-year-old female with right eye proptosis. Brain Pathology (Zurich, Switzerland). 21: 709-10. PMID 21995963 DOI: 10.1111/J.1750-3639.2011.00529.X  0.272
2019 Randazzo D, Achrol A, Aghi MK, Bexon M, Brem S, Brenner AJ, Butowski NA, Chandhasin C, Chowdhary SA, Coello M, Floyd J, Kesari S, Merchant F, Merchant N, Vogelbaum MA, et al. MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma. Journal of Clinical Oncology. 37: 2039-2039. DOI: 10.1200/Jco.2019.37.15_Suppl.2039  0.271
2018 Josephs SF, Ichim TE, Prince SM, Kesari S, Marincola FM, Escobedo AR, Jafri A. Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. Journal of Translational Medicine. 16: 242. PMID 30170620 DOI: 10.1186/S12967-018-1611-7  0.27
2017 Bhargava S, Visvanathan A, Patil V, Kumar A, Kesari S, Das S, Hegde AS, Arivazhagan A, Santosh V, Somasundaram K. IGF2 mRNA binding protein 3 (IMP3) promotes glioma cell migration by enhancing the translation of RELA/p65. Oncotarget. PMID 28465487 DOI: 10.18632/Oncotarget.17118  0.27
2015 Pingle SC, Jiang P, Mukthavaram R, Nomura N, Nair P, Kumar A, Singh N, Abbasi T, Vali S, Kesari S. Clinical translation pathway to Precision Medicine in GBM through simulation and repurposing. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E13041  0.27
2012 Li JC, Mahta A, Kim RY, Saria M, Kesari S. Cerebral syphilitic gumma: a case report and review of the literature. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 33: 1179-81. PMID 22167653 DOI: 10.1007/S10072-011-0878-8  0.269
2018 Stein MK, Martin MG, Xiu J, Mittal S, Phuphanich S, Provenzano AP, Michelhaugh S, Brenner AJ, Subramaniam DS, Sumrall AL, Heimberger AB, Kesari S, Korn WM, Pandey MK. Mutational complexity increases in lung adenocarcinoma (LADC) with the development of brain metastasis (BM). Journal of Clinical Oncology. 36: 2067-2067. DOI: 10.1200/Jco.2018.36.15_Suppl.2067  0.269
2018 Ichim TE, O'Heeron P, Kesari S. Fibroblasts as a practical alternative to mesenchymal stem cells. Journal of Translational Medicine. 16: 212. PMID 30053821 DOI: 10.1186/S12967-018-1536-1  0.268
2014 Hesselink JR, Barkovich MJ, Seibert TM, Farid N, Muller KA, Murphy KT, Kesari S. Bevacizumab: radiation combination produces restricted diffusion on brain MRI. Cns Oncology. 3: 329-35. PMID 25363005 DOI: 10.2217/Cns.14.35  0.268
2019 Sampson J, Achrol AS, Aghi M, Bankiewicz K, Brem S, Brenner A, Butowski N, Chandhasin C, Chowdhary S, Coello M, Floyd JR, Kesari S, Merchant F, Merchant N, Randazzo D, et al. Atim-30. Combating Recurrent Glioblastoma With Mdna55, An Interleukin-4 Receptor Targeted Immunotherapy, Through Mri-Guided Convective Delivery Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.029  0.266
2022 Ekhator C, Kesari S, Tadipatri R, Fonkem E, Grewal J. The Emergence of Virtual Tumor Boards in Neuro-Oncology: Opportunities and Challenges. Cureus. 14: e25682. PMID 35677741 DOI: 10.7759/cureus.25682  0.265
2012 Hu J, Kesari S. The molecular basis for novel therapies. Cancer Journal (Sudbury, Mass.). 18: 32-9. PMID 22290255 DOI: 10.1097/Ppo.0B013E3182455187  0.264
2012 Zhang M, Mahta A, Kim RY, Akar S, Kesari S. Durable remission of leptomeningeal metastases from hormone-responsive prostate cancer Medical Oncology. 29: 806-808. PMID 21424585 DOI: 10.1007/S12032-011-9906-Z  0.263
2010 Erten A, Hall D, Hoh C, Tran Cao HS, Kaushal S, Esener S, Hoffman RM, Bouvet M, Chen J, Kesari S, Makale M. Enhancing magnetic resonance imaging tumor detection with fluorescence intensity and lifetime imaging. Journal of Biomedical Optics. 15: 066012. PMID 21198186 DOI: 10.1117/1.3509111  0.263
2011 Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S, Verhaak R, Cherniack AD, Watanabe H, Dutt A, Kwon J, Chao YS, Onofrio RC, Chiang D, Yuza Y, ... Kesari S, et al. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Research. 71: 7587-96. PMID 22001862 DOI: 10.1158/0008-5472.Can-11-0821  0.262
2010 Zhang M, Li F, Rasper M, Saad AG, Kesari S. Prolonged stability of progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: e503-6. PMID 20585084 DOI: 10.1200/Jco.2009.26.8078  0.261
2011 Gheuens S, Bord E, Kesari S, Simpson DM, Gandhi RT, Clifford DB, Berger JR, Ngo L, Koralnik IJ. Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. Journal of Virology. 85: 7256-63. PMID 21543472 DOI: 10.1128/Jvi.02506-10  0.261
2016 Hope TR, White NS, Kuperman J, Chao Y, Yamin G, Bartch H, Schenker-Ahmed NM, Rakow-Penner R, Bussell R, Nomura N, Kesari S, Bjørnerud A, Dale AM. Demonstration of Non-Gaussian Restricted Diffusion in Tumor Cells Using Diffusion Time-Dependent Diffusion-Weighted Magnetic Resonance Imaging Contrast. Frontiers in Oncology. 6: 179. PMID 27532028 DOI: 10.3389/Fonc.2016.00179  0.26
2016 Hu J, Western S, Kesari S. Brainstem Glioma in Adults. Frontiers in Oncology. 6: 180. PMID 27556016 DOI: 10.3389/Fonc.2016.00180  0.259
2012 Ng K, Kim R, Kesari S, Carter B, Chen CC. Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. Journal of Neuro-Oncology. 107: 1-12. PMID 22002595 DOI: 10.1007/S11060-011-0714-2  0.259
2008 Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, Krichevsky AM. MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators Molecular and Cellular Biology. 28: 5369-5380. PMID 18591254 DOI: 10.1128/Mcb.00479-08  0.259
2011 Gabriely G, Yi M, Narayan RS, Niers JM, Wurdinger T, Imitola J, Ligon KL, Kesari S, Esau C, Stephens RM, Tannous BA, Krichevsky AM. Human glioma growth is controlled by microRNA-10b. Cancer Research. 71: 3563-72. PMID 21471404 DOI: 10.1158/0008-5472.Can-10-3568  0.258
2018 Ichim TE, Kesari S, Shafer K. Protection from chemotherapy- and antibiotic-mediated dysbiosis of the gut microbiota by a probiotic with digestive enzymes supplement. Oncotarget. 9: 30919-30935. PMID 30112118 DOI: 10.18632/Oncotarget.25778  0.257
2019 Yadavalli S, Yenugonda VM, Kesari S. Repurposed Drugs in Treating Glioblastoma Multiforme: Clinical Trials Update. Cancer Journal. 25: 139-146. PMID 30896537 DOI: 10.1097/Ppo.0000000000000365  0.256
2020 Allnutt AB, Waters AK, Kesari S, Yenugonda VM. Physiological and Pathological Roles of Cdk5: Potential Directions for Therapeutic Targeting in Neurodegenerative Disease. Acs Chemical Neuroscience. PMID 32286796 DOI: 10.1021/Acschemneuro.0C00096  0.256
2006 Ligon KL, Kesari S, Kitada M, Sun T, Arnett HA, Alberta JA, Anderson DJ, Stiles CD, Rowitch DH. Development of NG2 neural progenitor cells requires Olig gene function. Proceedings of the National Academy of Sciences of the United States of America. 103: 7853-8. PMID 16682644 DOI: 10.1073/Pnas.0511001103  0.255
2014 Morgan LL, Kesari S, Davis DL. Why children absorb more microwave radiation than adults: The consequences Journal of Microscopy and Ultrastructure. 2: 197-204. DOI: 10.1016/J.Jmau.2014.06.005  0.255
2011 Kesari S, Bota DA. Fos-related antigen-1 (Fra-1) is a regulator of glioma cell malignant phenotype Cancer Biology and Therapy. 11: 307-310. PMID 21242721 DOI: 10.4161/Cbt.11.3.14718  0.255
2010 Yavagal DR, Geng D, Akar S, Buonanno F, Kesari S. Superficial siderosis of the central nervous system due to bilateral jugular vein thrombosis Archives of Neurology. 67: 1269-1271. PMID 20937957 DOI: 10.1001/Archneurol.2010.255  0.254
2014 Jiang P, Xue D, Zhang Y, Ye L, Liu Y, Makale M, Kesari S, Edgington TS, Liu C. The extrinsic coagulation cascade and tissue factor pathway inhibitor in macrophages: a potential therapeutic opportunity for atherosclerotic thrombosis. Thrombosis Research. 133: 657-66. PMID 24485401 DOI: 10.1016/J.Thromres.2014.01.012  0.254
2008 Saad A, Tuli S, Ali EN, Houtchens M, Delalle I, Kesari S. Pilocytic astrocytoma of the spinal cord in an adult. Journal of Neuro-Oncology. 88: 189-91. PMID 18340405 DOI: 10.1007/S11060-008-9547-Z  0.253
2011 Young GS, Macklin EA, Setayesh K, Lawson JD, Wen PY, Norden AD, Drappatz J, Kesari S. Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. Journal of Neuro-Oncology. 104: 261-9. PMID 21132516 DOI: 10.1007/s11060-010-0477-1  0.253
2012 Imitola J, Pitt K, Peoples JL, Krynska B, Sheikh H, Kesari S, Azizi SA. Multifocal CNS infiltration of chronic lymphocytic leukemia in the form of small-cell solid metastatic lesions. Journal of Neuro-Oncology. 109: 213-5. PMID 22573347 DOI: 10.1007/S11060-012-0869-5  0.253
2012 Kanakamedala MR, Mahta A, Liu J, Kesari S. Late temporal lobe necrosis after conventional radiotherapy for carcinoma of maxillary sinus. Medical Oncology (Northwood, London, England). 29: 2456-8. PMID 22246565 DOI: 10.1007/S12032-011-0141-4  0.253
2014 Mukthavaram R, Shi G, Kesari S, Simberg D. Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes. Journal of Controlled Release : Official Journal of the Controlled Release Society. 183: 146-53. PMID 24685706 DOI: 10.1016/J.Jconrel.2014.03.038  0.252
2019 Murphy M, Dowling A, Thien C, Priest E, Morgan Murray D, Kesari S. A feasibility study of the Nativis Voyager device in patients with recurrent glioblastoma in Australia. Cns Oncology. CNS. PMID 30727742 DOI: 10.2217/Cns-2018-0017  0.251
2014 Li L, Chakraborty S, Yang CR, Hatanpaa KJ, Cipher DJ, Puliyappadamba VT, Rehman A, Jiwani AJ, Mickey B, Madden C, Raisanen J, Burma S, Saha D, Wang Z, Pingle SC, ... Kesari S, et al. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII. Oncogene. 33: 4253-64. PMID 24077285 DOI: 10.1038/Onc.2013.400  0.25
2012 Mahta A, Kim RY, Kesari S. Levetiracetam-induced interstitial nephritis in a patient with glioma. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 19: 177-8. PMID 22071460 DOI: 10.1016/J.Jocn.2011.08.007  0.25
2013 Campian J, Gladstone D, Ambady P, Ye X, King K, Borrello I, Petrik S, Golightly M, Holdhoff M, Grossman S, Bhardwaj R, Chakravadhanula M, Ozols V, Georges J, Carlson E, ... ... Kesari S, et al. IMMUNOTHERAPY/BIOLOGICAL THERAPIES Neuro-Oncology. 15: iii68-iii74. DOI: 10.1093/Neuonc/Not178  0.25
2008 Drappatz J, Akar S, Fisher DC, Samuels MA, Kesari S. Imaging of Bing-Neel syndrome. Neurology. 70: 1364. PMID 18413593 DOI: 10.1212/01.Wnl.0000309212.22661.84  0.249
2006 Wüthrich C, Kesari S, Kim WK, Williams K, Gelman R, Elmeric D, De Girolami U, Joseph JT, Hedley-Whyte T, Koralnik IJ. Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(+) T cells with JCV-infected glial cells. Journal of Neurovirology. 12: 116-28. PMID 16798673 DOI: 10.1080/13550280600716604  0.247
2018 Riordan NH, Morales I, Fernández G, Allen N, Fearnot NE, Leckrone ME, Markovich DJ, Mansfield D, Avila D, Patel AN, Kesari S, Paz Rodriguez J. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. Journal of Translational Medicine. 16: 57. PMID 29523171 DOI: 10.1186/S12967-018-1433-7  0.247
2006 Kesari S, Stiles CD. The bad seed: PDGF receptors link adult neural progenitors to glioma stem cells. Neuron. 51: 151-3. PMID 16846849 DOI: 10.1016/J.Neuron.2006.07.001  0.247
2011 Mukthavaram R, Wrasidlo W, Hall D, Kesari S, Makale M. Assembly and targeting of liposomal nanoparticles encapsulating quantum dots. Bioconjugate Chemistry. 22: 1638-44. PMID 21786821 DOI: 10.1021/Bc200201E  0.247
2013 Elbabaa SK, Gokden M, Crawford J, Kesari S, Saad AG. 122 Pediatric Radiation-Associated Meningiomas: Distinct Clinical, Pathological, and Cytogenetic Characteristics Neurosurgery. 60: 160. DOI: 10.1227/01.Neu.0000432713.86251.03  0.247
2016 Saria MG, Courchesne N, Evangelista L, Carter J, MacManus DA, Gorman MK, Nyamathi AM, Phillips LR, Piccioni D, Kesari S, Maliski S. Cognitive dysfunction in patients with brain metastases: influences on caregiver resilience and coping. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 27921222 DOI: 10.1007/S00520-016-3517-3  0.247
2016 Cloughesy TF, Aghi M, Bota D, Chen C, Elder JB, Kalkanis SN, Kaptain GJ, Kesari S, Landolfi J, Mikkelsen T, Portnow J, Robbins JM, Ostertag D, Chu A, Huang T, et al. Prior Radiation in Subjects Who Were Treated With Toca 511 and Toca FC Across 3 Toca 511 Phase 1 Trials. International Journal of Radiation Oncology, Biology, Physics. 96: E66-E67. PMID 27675287 DOI: 10.1016/J.Ijrobp.2016.06.758  0.247
2017 Saria MG, Courchesne NS, Evangelista L, Carter JL, MacManus DA, Gorman MK, Nyamathi AM, Phillips LR, Piccioni DE, Kesari S, Maliski SL. Anxiety and Depression Associated With Burden in Caregivers of Patients With Brain Metastases. Oncology Nursing Forum. 44: 306-315. PMID 28635984 DOI: 10.1188/17.Onf.306-315  0.247
2016 Hodges T, Sanai N, Xiu J, Kim L, Zhou S, Kesari S, Penas-Prado M, Heimberger A. Mpth-45. Medulloblastoma: Candidate Pathways For Novel Treatment Strategies Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.480  0.245
2017 Alton GR, Beaton G, Knowles S, Stein G, Kesari S. Abstract 1174: CT179 degrades the olig2 transcription factor in glioblastoma stem-like cells and prolongs survival Cancer Research. 77: 1174-1174. DOI: 10.1158/1538-7445.Am2017-1174  0.245
2023 Kesari S, Williams J, Burbano E, Stirn M, Caroen S, Oronsky B, Reid T, Larson C. Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient. Case Reports in Oncology. 16: 172-176. PMID 37008834 DOI: 10.1159/000529503  0.244
2016 Alton G, Kesari S. Novel small molecule inhibitors of the OLIG2 transcription factor: Promising new therapeutics for glioblastoma Future Oncology. 12: 1001-1004. DOI: 10.2217/Fon-2015-0078  0.244
2019 Babic I, Kesari S, Glassy MC. A Binding Potency Assay for Pritumumab and Ecto-Domain Vimentin. Methods of Molecular Biology. 1904: 401-415. PMID 30539482 DOI: 10.1007/978-1-4939-8958-4_19  0.243
2016 Huang TT, Aghi MK, Chen CC, Elder JB, Kesari S, Kalkanis S, Kaptain G, Landolfi J, Mikkelsen T, Portnow J, Robbins JM, Ostertag D, Das A, Chu A, Vogelbaum MA. OS8 - 150 Encouraging Survival with Toca 511 and Toca FC Compared to External Lomustine Control Canadian Journal of Neurological Sciences. 43. DOI: 10.1017/Cjn.2016.339  0.243
2017 Dobrovolsky A, Ichim TE, Ma D, Kesari S, Bogin V. Xenon in the treatment of panic disorder: an open label study. Journal of Translational Medicine. 15: 137. PMID 28610592 DOI: 10.1186/S12967-017-1237-1  0.243
2020 Cheltsov A, Nomura N, Yenugonda VM, Roper J, Mukthavaram R, Jiang P, Her NG, Babic I, Kesari S, Nurmemmedov E. Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancer. Scientific Reports. 10: 8096. PMID 32415084 DOI: 10.1038/S41598-020-60784-Y  0.242
2020 Her NG, Babic I, Yenugonda VM, Kesari S, Nurmemmedov E. Cellular thermal shift analysis for interrogation of CRISPR-assisted proteomic changes. Biotechniques. PMID 32040335 DOI: 10.2144/Btn-2019-0100  0.242
2007 Khwaja FW, Reed MS, Olson JJ, Schmotzer BJ, Gillespie GY, Guha A, Groves MD, Kesari S, Pohl J, Van Meir EG. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. Journal of Proteome Research. 6: 559-70. PMID 17269713 DOI: 10.1021/Pr060240Z  0.241
2016 Brunsing RL, Schenker-Ahmed NM, White NS, Parsons JK, Kane C, Kuperman J, Bartsch H, Kader AK, Rakow-Penner R, Seibert TM, Margolis D, Raman SS, McDonald CR, Farid N, Kesari S, et al. Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI. Journal of Magnetic Resonance Imaging : Jmri. PMID 27527500 DOI: 10.1002/Jmri.25419  0.241
2015 Makale M, Kesari S. Cell Phones and Glioma Risk: An Update Neuro-Oncology Practice. 5: 24-36. DOI: 10.1093/Nop/Npv045  0.241
2019 Picconi D, Juarez T, Kesari S. Actr-56. Phase Ii Trial Of Nilotinib In Pdgfr-Alpha Enriched Recurrent Glioblastoma Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.098  0.241
2016 Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, ... Kesari S, et al. RRx-001: A Systemically Non-Toxic M2-to-M1 Macrophage Stimulating and Prosensitizing Agent In Phase II Clinical Trials. Expert Opinion On Investigational Drugs. PMID 27935336 DOI: 10.1080/13543784.2017.1268600  0.239
2012 Fu H, Kesari S, Cai J. Tcf7l2 is tightly controlled during myelin formation. Cellular and Molecular Neurobiology. 32: 345-52. PMID 22160878 DOI: 10.1007/S10571-011-9778-Y  0.238
2016 Nomura N, Nurmemmedov E, Ravula S, Kouznetsova V, Tsigelny I, Yenugonda V, Kesari S, Babic I. DDIS-17. SMALL MOLECULE INHIBITORS OF C1qBP FOR THERAPEUTIC INTERVENTION IN GLIOMA Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.208  0.238
2017 Nandu H, Kijewski MF, Dubey S, Belanger AP, Reardon D, Wen P, Kesari S, Horky L, Park M, Huang RY. P09.13 F-18 FLT PET and MRI as outcome predictors in glioblastomas following chemoradiation therapy Neuro-Oncology. 19: iii72-iii73. DOI: 10.1093/Neuonc/Nox036.271  0.238
2022 Kesari S, Bessudo A, Gastman BR, Conley AP, Villaflor VM, Nabell LM, Madere D, Chacon E, Spencer C, Li L, Larson C, Reid T, Caroen S, Oronsky B, Stirn M, et al. BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors. Future Oncology (London, England). PMID 35950603 DOI: 10.2217/fon-2022-0481  0.237
2016 Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, ... ... Kesari S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12: 1-222. PMID 26799652 DOI: 10.1080/15548627.2015.1100356  0.237
2011 Larman HB, Zhao Z, Laserson U, Li MZ, Ciccia A, Gakidis MA, Church GM, Kesari S, Leproust EM, Solimini NL, Elledge SJ. Autoantigen discovery with a synthetic human peptidome. Nature Biotechnology. 29: 535-41. PMID 21602805 DOI: 10.1038/Nbt.1856  0.236
2003 Kesari S, Batchelor TT. Leptomeningeal metastases. Neurologic Clinics. 21: 25-66. PMID 12690644 DOI: 10.1016/s0733-8619(02)00032-4  0.236
2013 Rosenberg J, Mahta A, Koppula K, Borys E, Kesari S. Cyclophosphamide responsive primary angiitis of the CNS in a 61-year-old female. Clinical Neuropathology. 32: 66-8. PMID 23006473 DOI: 10.5414/Np300513  0.234
2017 Mikirova NA, Kesari S, Ichim TE, Riordan NH. Effect of Infla-Kine supplementation on the gene expression of inflammatory markers in peripheral mononuclear cells and on C-reactive protein in blood Journal of Translational Medicine. 15: 213-213. PMID 29058588 DOI: 10.1186/S12967-017-1315-4  0.233
2020 Wagle N, Nguyen M, Carrillo J, Truong J, Dobrawa L, Kesari S. Characterization of molecular pathways for targeting therapy in glioblastoma. Chinese Clinical Oncology. PMID 33353366 DOI: 10.21037/cco-20-124  0.233
2022 Patro CPK, Biswas N, Pingle SC, Lin F, Anekoji M, Jones LD, Kesari S, Wang F, Ashili S. MTAP loss: a possible therapeutic approach for glioblastoma. Journal of Translational Medicine. 20: 620. PMID 36572880 DOI: 10.1186/s12967-022-03823-8  0.231
2019 Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives. International Journal of Nanomedicine. 14: 1937-1952. PMID 30936695 DOI: 10.2147/Ijn.S198353  0.23
2014 Shi G, Mukthavaram R, Kesari S, Simberg D. Distearoyl anchor-painted erythrocytes with prolonged ligand retention and circulation properties in vivo. Advanced Healthcare Materials. 3: 142-8. PMID 23798381 DOI: 10.1002/Adhm.201300084  0.23
2004 Kesari S. Digital rendition of visual migraines. Jama Neurology. 61: 1464-1465. PMID 15364697 DOI: 10.1001/Archneur.61.9.1464  0.229
2023 Sampson JH, Singh Achrol A, Aghi MK, Bankiewiecz K, Bexon M, Brem S, Brenner A, Chandhasin C, Chowdhary S, Coello M, Ellingson BM, Floyd JR, Han S, Kesari S, Mardor Y, et al. Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial. Neuro-Oncology. PMID 36640127 DOI: 10.1093/neuonc/noac285  0.229
2022 Pandey M, Xiu J, Mittal S, Zeng J, Saul M, Kesari S, Azadi A, Newton H, Deniz K, Ladner K, Sumrall A, Korn WM, Lou E. Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields. Neuro-Oncology Advances. 4: vdac096. PMID 35821680 DOI: 10.1093/noajnl/vdac096  0.229
2013 Zhu J, Larman HB, Gao G, Somwar R, Zhang Z, Laserson U, Ciccia A, Pavlova N, Church G, Zhang W, Kesari S, Elledge SJ. Protein interaction discovery using parallel analysis of translated ORFs (PLATO). Nature Biotechnology. 31: 331-4. PMID 23503679 DOI: 10.1038/Nbt.2539  0.229
2023 Kesari S, Wang F, Juarez T, Ashili S, Patro CPK, Carrillo J, Nguyen M, Truong J, Levy J, Sommer J, Freed DM, Xiu J, Takasumi Y, Bouffet E, Gill JM. Activity of pemetrexed in pre-clinical chordoma models and humans. Scientific Reports. 13: 7317. PMID 37147496 DOI: 10.1038/s41598-023-34404-4  0.229
2021 Yalamanchi A, Gill JM, Truong J, Nguyen M, Carrillo J, Wagle N, Sharma A, Kesari S. Molecularly targeted treatment of recurrent anaplastic astrocytoma - a case report. Annals of Clinical and Translational Neurology. PMID 34328281 DOI: 10.1002/acn3.51430  0.227
2018 Babic I, Kesari S, Nurmemmedov E. Cellular target engagement: a new paradigm in drug discovery. Future Medicinal Chemistry. 10: 1641-1644. PMID 29957028 DOI: 10.4155/Fmc-2018-0139  0.227
2018 Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, ... ... Kesari S, et al. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine. 16: 179. PMID 29958537 DOI: 10.1186/S12967-018-1552-1  0.225
2012 Hu J, Kesari S. General Aspects of Chemotherapy Including "Biologic Agents" Neuro-Oncology: First Edition. 44-59. DOI: 10.1002/9781118321478.ch5  0.225
2020 Crawford J, Saria MG, Dhall G, Margol A, Kesari S. Feasibility of Treating High Grade Gliomas in Children with Tumor-Treating Fields: A Case Series. Cureus. 12: e10804. PMID 33163308 DOI: 10.7759/cureus.10804  0.224
2011 Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, Kesari S, Furnari F, Hoadley KA, Chin L, DePinho RA, Cavenee WK, D'Andrea A, Chen CC. Correction: Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy Plos One. 6. DOI: 10.1371/Annotation/9B9Cc4Ae-Ad56-464F-Ab97-59F096B5C0Eb  0.224
2019 Waters A, Nurmammadov E, Nomura N, Babic I, Kesari S, Yenugonda V. Ddis-37. Small Molecule Autophagy Activators In Growth Inhibition Of Glioblastoma Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.288  0.224
2014 White N, McDonald C, Farid N, Kuperman J, Karow D, Schenker-Ahmed N, Bartsch H, Rakow-Penner R, Holland D, Shabaik A, Bjørnerud A, Hope T, Hattangadi-Gluth J, Liss M, Parsons J, ... ... Kesari S, et al. Erratum: Diffusion-Weighted imaging in cancer: Physical foundations and applications of restriction spectrum imaging (Cancer Research (2014) 74 (4638-4652)) Cancer Research. 74: 6733. DOI: 10.1158/0008-5472.Can-14-2893  0.223
2017 Shi G, Jin L, Matter ML, Kesari S, Ramos JW. Abstract 1363: RSK2 provokes invasive signaling in glioblastoma through LARG-dependent activation of Rho GTPases Cancer Research. 77: 1363-1363. DOI: 10.1158/1538-7445.Am2017-1363  0.223
2006 Norden AD, Wen PY, Kesari S. Brain metastases. Current Opinion in Neurology. 18: 654-61. PMID 16280676 DOI: 10.1097/01.wco.0000191514.37498.2b  0.222
2023 Conley AP, Roland CL, Bessudo A, Gastman BR, Villaflor VM, Larson C, Reid TR, Caroen S, Oronsky B, Stirn M, Williams J, Burbano E, Coyle A, Barve MA, Wagle N, ... ... Kesari S, et al. BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors. Cancer Gene Therapy. PMID 38146006 DOI: 10.1038/s41417-023-00720-0  0.222
2013 Akers JC, Ramakrishnan V, Kim R, Skog J, Nakano I, Pingle S, Kalinina J, Hua W, Kesari S, Mao Y, Breakefield XO, Hochberg FH, Van Meir EG, Carter BS, Chen CC. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. Plos One. 8: e78115. PMID 24205116 DOI: 10.1371/Journal.Pone.0078115  0.221
2013 Chao Y, Karmali PP, Mukthavaram R, Kesari S, Kouznetsova VL, Tsigelny IF, Simberg D. Direct recognition of superparamagnetic nanocrystals by macrophage scavenger receptor SR-AI. Acs Nano. 7: 4289-98. PMID 23614696 DOI: 10.1021/Nn400769E  0.221
2007 Wabulya A, Imitola J, Santagata S, Kesari S. Mycosis fungoides with leptomeningeal involvement. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 5658-61. PMID 18065739 DOI: 10.1200/Jco.2007.14.3800  0.22
2013 Nozawa A, Rivandi AH, Kesari S, Hoh CK. Glucose corrected standardized uptake value (SUVgluc) in the evaluation of brain lesions with 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging. 40: 997-1004. PMID 23571761 DOI: 10.1007/S00259-013-2396-9  0.22
2024 Marallano VJ, Ughetta ME, Tejero R, Nanda S, Ramalingam R, Stalbow L, Sattiraju A, Huang Y, Ramakrishnan A, Shen L, Wojcinski A, Kesari S, Zou H, Tsankov AM, Friedel RH. Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines. Scientific Reports. 14: 7246. PMID 38538643 DOI: 10.1038/s41598-024-56102-5  0.219
2010 Grewal J, Zhou H, Factor R, Kesari S. Isolated loss of hormonal receptors in leptomeningeal metastasis from estrogen receptor- and progesterone receptor-positive lobular breast cancer Journal of Clinical Oncology. 28: e200-e202. DOI: 10.1200/Jco.2009.25.3518  0.218
2023 Kesari S, Wagle N, Carrillo JA, Sharma A, Nguyen M, Truong J, Gill JM, Nersesian R, Nomura N, Rahbarlayegh E, Barkhoudarian G, Sivakumar W, Kelly DF, Krauss H, Bustos MA, et al. Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF11. PMID 38047868 DOI: 10.1158/1078-0432.CCR-23-2317  0.218
2016 Camelo-Piragua S, Kesari S. Further understanding of the pathology of glioma: implications for the clinic. Expert Review of Neurotherapeutics. PMID 27228211 DOI: 10.1080/14737175.2016.1194755  0.217
2010 Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S, Ho VT, Stone RM, Mullally A. CNS relapse in acute promyeloctyic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: e409-11. PMID 20530270 DOI: 10.1200/Jco.2009.27.1577  0.217
2012 Freudiger CW, Pfannl R, Orringer DA, Saar BG, Ji M, Zeng Q, Ottoboni L, Wei Y, Ying W, Waeber C, Sims JR, De Jager PL, Sagher O, Philbert MA, Xu X, ... Kesari S, et al. Multicolored stain-free histopathology with coherent Raman imaging. Laboratory Investigation; a Journal of Technical Methods and Pathology. 92: 1492-502. PMID 22906986 DOI: 10.1038/Labinvest.2012.109  0.217
2021 Fu S, Piccioni DE, Liu H, Lukas RV, Kesari S, Aregawi D, Hong DS, Yamaguchi K, Whicher K, Zhang Y, Chen YL, Poola N, Eddy J, Blum D. A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. Scientific Reports. 11: 22355. PMID 34785698 DOI: 10.1038/s41598-021-01707-3  0.215
2016 Babic I, Mukthavaram R, Jiang P, Nomura N, Pingle S, Glassy M, Kesari S. IMST-57. THERAPEUTIC POTENTIAL OF THE NATURAL HUMAN IgG1k ANTIBODY PRITUMUMAB Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.413  0.215
2008 Rasper M, Kesari S. Burkitt lymphoma presenting as a rapidly evolving cavernous sinus syndrome. Jama Neurology. 65: 1668-1668. PMID 19064758 DOI: 10.1001/Archneur.65.12.1668  0.215
2012 Chao Y, Makale M, Karmali PP, Sharikov Y, Tsigelny I, Merkulov S, Kesari S, Wrasidlo W, Ruoslahti E, Simberg D. Recognition of dextran-superparamagnetic iron oxide nanoparticle conjugates (Feridex) via macrophage scavenger receptor charged domains. Bioconjugate Chemistry. 23: 1003-9. PMID 22515422 DOI: 10.1021/Bc200685A  0.214
2023 Li Y, Lim C, Dismuke T, Malawsky D, Oasa S, Bruce Z, Offenhäuser C, Baumgartner U, D'Souza R, Edwards S, French J, Ock L, Nair S, Sivakumaran H, Harris L, ... ... Kesari S, et al. Preventing recurrence in Sonic Hedgehog Subgroup Medulloblastoma using OLIG2 inhibitor CT-179. Research Square. PMID 37333134 DOI: 10.21203/rs.3.rs-2949436/v1  0.213
2023 Liu A, Alalami H, Fan X, Patil C, Gill JM, Kesari S, Hu J. Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS. Cns Oncology. CNS100. PMID 37435740 DOI: 10.2217/cns-2022-0021  0.213
2015 Ibsen S, Sonnenberg A, Schutt C, Mukthavaram R, Yeh Y, Ortac I, Manouchehri S, Kesari S, Esener S, Heller MJ. Recovery of Drug Delivery Nanoparticles from Human Plasma Using an Electrokinetic Platform Technology. Small (Weinheim An Der Bergstrasse, Germany). PMID 26274918 DOI: 10.1002/Smll.201500892  0.212
2014 Jung JY, Hirata GA, Gundiah G, Derenzo S, Wrasidlo W, Kesari S, Makale MT, McKittrick J. Identification and development of nanoscintillators for biotechnology applications Journal of Luminescence. 154: 569-577. DOI: 10.1016/J.Jlumin.2014.05.040  0.212
2018 Babic I, Yenugonda VM, Kesari S, Nurmemmedov E. Wnt pathway: a hallmark of drug discovery challenge. Future Medicinal Chemistry. PMID 29779411 DOI: 10.4155/Fmc-2018-0084  0.212
2012 Freudiger CW, Pfannl R, Orringer DA, Saar BG, Ji M, Zeng Q, Ottoboni L, Ying W, Waeber C, Sims JR, De Jager PL, Sagher O, Philbert MA, Xu X, Kesari S, et al. Erratum: Multicolored stain-free histopathology with coherent Raman imaging Laboratory Investigation. 92: 1661-1661. DOI: 10.1038/Labinvest.2012.139  0.211
2017 Krauss HR, Kelly DF, Barkhoudarian G, Kesari S, Griffiths CF, Flores E. The Clinical Utility of Ocular Coherence Tomography in Evaluation and Management of Skull Base Disorders Skull Base Surgery. 78. DOI: 10.1055/S-0037-1600660  0.209
2018 Graber JJ, Kesari S. Leptomeningeal Metastases. Current Treatment Options in Oncology. 19: 3. PMID 29362920 DOI: 10.1007/s11864-018-0518-0  0.208
2023 Barkhoudarian G, Badruddoja M, Blondin N, Chowdhary S, Cobbs C, Duic JP, Flores JP, Fonkem E, McClay E, Nabors LB, Salacz M, Taylor L, Vaillant B, Gill J, Kesari S. An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma. Cns Oncology. CNS102. PMID 37462385 DOI: 10.2217/cns-2022-0016  0.208
2016 Nurmemmedov E, Kesari S. DDIS-18. A NOVEL INHIBITOR OF β-CATENIN SELECTIVELY HALTS ONCOGENIC WNT SIGNALING Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.209  0.206
2008 Kesari S, Drappatz J, Akar S, Vergilio JA, Wen PY, Soiffer RJ, Stone RM, Deangelo DJ. Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass Journal of Clinical Oncology. 26: 3279-3281. PMID 18591563 DOI: 10.1200/Jco.2007.15.6729  0.204
2004 Kesari S, Bundock EA. Punched-out skull. Archives of Neurology. 61: 958-9. PMID 15210540 DOI: 10.1001/Archneur.61.6.958  0.204
2011 Erten A, Makale M, Lu X, Fruhberger B, Kesari S, Esener S. Streamlined cryogenic deep reactive ion etching protocol for hybrid micronozzle arrays Journal of Micromechanics and Microengineering. 21. DOI: 10.1088/0960-1317/21/10/105001  0.202
2007 Santagata S, Kesari S, Black PM, Chan JA. Anaplastic variant of medulloblastoma mimicking a vestibular schwannoma. Journal of Neuro-Oncology. 81: 49-51. PMID 17146596 DOI: 10.1007/S11060-006-9235-9  0.202
2016 van Vugt VA, Kesari A, Muller KA, Carter B, Vandenberg SR, Kesari S. A 22-Year Old Woman with Right Eyelid Swelling. Brain Pathology (Zurich, Switzerland). 26: 425-426. PMID 27111386 DOI: 10.1111/Bpa.12381  0.2
2015 Ibsen S, Sonnenberg A, Schutt C, Mukthavaram R, Yeh Y, Ortac I, Manouchehri S, Kesari S, Esener S, Heller MJ. Nanoparticles: Recovery of Drug Delivery Nanoparticles from Human Plasma Using an Electrokinetic Platform Technology (Small 38/2015). Small (Weinheim An Der Bergstrasse, Germany). 11: 4990. PMID 26450159 DOI: 10.1002/Smll.201570233  0.199
2011 Kesari S. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Seminars in Oncology. 38: S2-10. PMID 22078644 DOI: 10.1053/j.seminoncol.2011.09.005  0.196
2018 Phuphanich S, Sanai N, Xiu J, Mittal S, Michelhaugh S, Subramaniam DS, Pandey MK, Kesari S, Heimberger AB, Gatalica Z, Korn WM, Sumrall AL. P01.058 Higher immune associated markers (PD-L1, PD-1, TMB, MSI) in gliosarcoma compared to glioblastoma. Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy139.100  0.196
2014 Mahta A, Borys E, Vandenberg SR, Carter B, Kesari S. 72 year old female with leg weakness. Brain Pathology (Zurich, Switzerland). 24: 195-6. PMID 25121191 DOI: 10.1111/Bpa.12123  0.196
2017 Huang Y, Tejero-Villalba R, Kesari S, Zou H, Friedel R. Angi-19. The Axon Guidance Receptor Plexin-B2 Promotes Tumorigenicity Of Glioblastoma Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.097  0.195
2021 Dardis C, Donner D, Sanai N, Xiu J, Mittal S, Michelhaugh SK, Pandey M, Kesari S, Heimberger AB, Gatalica Z, Korn MW, Sumrall AL, Phuphanich S. Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling. Bmc Neurology. 21: 231. PMID 34162346 DOI: 10.1186/s12883-021-02233-5  0.195
2021 Bota DA, Mason W, Kesari S, Magge R, Winograd B, Elias I, Reich SD, Levin N, Trikha M, Desjardins A. Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. Neuro-Oncology Advances. 3: vdab142. PMID 34729484 DOI: 10.1093/noajnl/vdab142  0.195
2017 van Vugt VA, Saria MG, Javier A, Kesari N, Turpin T, Kesari S. Neurological improvement of perineural and leptomeningeal spread of squamous cell carcinoma treated with intrathecal chemotherapy and systemic EGFR inhibition. Cns Oncology. PMID 28984139 DOI: 10.2217/cns-2017-0010  0.191
2012 Lin N, Huttner A, Spieler P, Claus EB, Kesari S. 55-year-old female with low back pain. Brain Pathology (Zurich, Switzerland). 22: 427-8. PMID 22497615 DOI: 10.1111/J.1750-3639.2012.00589.X  0.19
2009 Saad AG, Alyea EP, Wen PY, Degirolami U, Kesari S. Graft-versus-host disease of the CNS after allogeneic bone marrow transplantation Journal of Clinical Oncology. 27: e147-e149. PMID 19667266 DOI: 10.1200/Jco.2009.21.7919  0.19
2021 Ellingson BM, Sampson JH, Achrol AS, Aghi MK, Krystof Bankiewicz K, Wang C, Bexon M, Brem S, Brenner AJ, Chowdhary S, Floyd JR, Han SJ, Kesari S, Randazzo D, Vogelbaum MA, et al. Modified RANO (mRANO), iRANO, and standard RANO response to convection-enhanced delivery of IL4R-targeted immunotoxin MDNA55 in recurrent glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33863808 DOI: 10.1158/1078-0432.CCR-21-0446  0.186
2013 Ambady P, Holdhoff M, Ferrigno C, Grossman S, Anderson MD, Liu D, Conrad C, Penas-Prado M, Gilbert MR, Yung AWK, Groot Jd, Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, ... ... Kesari S, et al. Neuro/Medical Oncology Neuro-Oncology. 15: 120-120. DOI: 10.1093/Neuonc/Not182  0.184
2011 Prithviraj GK, Sommers SR, Jump RL, Halmos B, Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC, Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC, Hunter K, ... ... Kesari S, ... ... Kesari S, et al. MEDICAL AND NEURO-ONCOLOGY Neuro-Oncology. 13: iii41-iii68. DOI: 10.1093/Neuonc/Nor152  0.184
2016 Raza S, Sanai N, Xiu J, Kim L, Kesari S, Zhou S, Heimberger A. Mngo-10. Pd-1/Pd-L1 And Genomic Expression Profiling Of Meningiomas Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.431  0.183
2023 Darabi S, Xiu J, Samec T, Kesari S, Carrillo J, Aulakh S, Walsh KM, Sengupta S, Sumrall A, Spetzler D, Glantz M, Demeure MJ. Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target. Medical Oncology (Northwood, London, England). 40: 197. PMID 37291277 DOI: 10.1007/s12032-023-02071-0  0.183
2021 Latour M, Her NG, Kesari S, Nurmemmedov E. WNT Signaling as a Therapeutic Target for Glioblastoma. International Journal of Molecular Sciences. 22. PMID 34445128 DOI: 10.3390/ijms22168428  0.181
2021 Juarez TM, Piccioni D, Rose L, Nguyen A, Brown B, Kesari S. Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer. Neuro-Oncology Advances. 3: vdab006. PMID 33615223 DOI: 10.1093/noajnl/vdab006  0.181
2022 Bota DA, Taylor TH, Piccioni DE, Duma CM, LaRocca RV, Kesari S, Carrillo JA, Abedi M, Aiken RD, Hsu FPK, Kong XT, Hsieh C, Bota PG, Nistor GI, Keirstead HS, et al. Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. Journal of Experimental & Clinical Cancer Research : Cr. 41: 344. PMID 36517865 DOI: 10.1186/s13046-022-02552-6  0.179
2022 Weidhaas J, Marco N, Scheffler AW, Kalbasi A, Wilenius K, Rietdorf E, Gill J, Heilig M, Desler C, Chin RK, Kaprealian T, McCloskey S, Raldow A, Raja NP, Kesari S, et al. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. Journal For Immunotherapy of Cancer. 10. PMID 35115362 DOI: 10.1136/jitc-2021-003625  0.177
2009 Zhao H, Zhu J, Cui K, Xu X, O'Brien M, Wong KK, Kesari S, Xia W, Wong ST. Bioluminescence imaging reveals inhibition of tumor cell proliferation by Alzheimer's amyloid beta protein. Cancer Cell International. 9: 15. PMID 19480719 DOI: 10.1186/1475-2867-9-15  0.171
2011 Mou X, Kesari S, Wen PY, Huang X. Crude drugs as anticancer agents International Journal of Clinical and Experimental Medicine. 4: 17-25.  0.17
2011 Mou X, Kesari S, Wen PY, Huang X. Crude drugs as anticancer agents. International Journal of Clinical and Experimental Medicine. 4: 17-25. PMID 21394282  0.169
2024 Mukthavaram R, Jiang P, Pastorino S, Nomura N, Lin F, Kesari S. Evaluation of the EMulate Therapeutics Voyager's ultra-low radiofrequency energy in murine model of glioblastoma. Bioelectronic Medicine. 10: 10. PMID 38594769 DOI: 10.1186/s42234-024-00143-8  0.168
2023 Lin F, Lin EZ, Anekoji M, Ichim TE, Hu J, Marincola FM, Jones LD, Kesari S, Ashili S. Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines. Journal of Translational Medicine. 21: 830. PMID 37978542 DOI: 10.1186/s12967-023-04724-0  0.167
2013 Scott BJ, Kesari S. Leptomeningeal metastases in breast cancer. American Journal of Cancer Research. 3: 117-26. PMID 23593536  0.165
2010 Pothiawala S, Hsu MY, Yang C, Kesari S, Ibrahimi OA. Urticarial hypersensitivity reaction caused by temozolomide. Journal of Drugs in Dermatology : Jdd. 9: 1142-4. PMID 20865848  0.163
2022 Bustos MA, Rahimzadeh N, Ryu S, Gross R, Tran LT, Renteria-Lopez VM, Ramos RI, Eisenberg A, Hothi P, Kesari S, Barkhoudarian G, Takasumi Y, Cobbs C, Kelly DF, Hoon DSB. Cell-free plasma microRNAs that identify patients with glioblastoma. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 35013528 DOI: 10.1038/s41374-021-00720-4  0.162
2022 Perez JA, Lopez JJ, Torres Badillo CC, Gill J, Kesari S, Novak P, Temnikov M, Byshovets R, Bychkov O. Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases. Cureus. 14: e29921. PMID 36381721 DOI: 10.7759/cureus.29921  0.159
2020 Her NG, Kesari S, Nurmemmedov E. Thrombospondin-1 counteracts the p97 inhibitor CB-5083 in colon carcinoma cells. Cell Cycle (Georgetown, Tex.). 1-12. PMID 32423265 DOI: 10.1080/15384101.2020.1754584  0.158
2022 Hammond TC, Lee RC, Oronsky B, Reid TR, Caroen S, Juarez TM, Gill J, Heng A, Kesari S. Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001. International Medical Case Reports Journal. 15: 735-738. PMID 36545548 DOI: 10.2147/IMCRJ.S389690  0.155
2020 Ou A, Sumrall A, Phuphanich S, Spetzler D, Gatalica Z, Xiu J, Michelhaugh S, Brenner A, Pandey M, Kesari S, Korn WM, Mittal S, Westin J, Heimberger AB. Primary CNS lymphoma commonly expresses immune response biomarkers. Neuro-Oncology Advances. 2: vdaa018. PMID 32201861 DOI: 10.1093/noajnl/vdaa018  0.151
2023 Szu JI, Tsigelny IF, Wojcinski A, Kesari S. Biological functions of the Olig gene family in brain cancer and therapeutic targeting. Frontiers in Neuroscience. 17: 1129434. PMID 37274223 DOI: 10.3389/fnins.2023.1129434  0.15
2023 Perez JA, Parcero Valdes JJ, Corral Moreno R, Gomez Cuevas LI, Lopez JJ, Ichim T, McGreevy K, Lin F, Kesari S, Datta S. Intravenous Administration of Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSC) for Acute Respiratory Distress Syndrome Due to COVID-19 Infection. Cureus. 15: e44110. PMID 37638263 DOI: 10.7759/cureus.44110  0.143
2021 Bonm A, Kesari S. DNA Damage Response in Glioblastoma: Mechanism for Treatment Resistance and Emerging Therapeutic Strategies. Cancer Journal (Sudbury, Mass.). 27: 379-385. PMID 34570452 DOI: 10.1097/PPO.0000000000000540  0.143
2021 Solano-Gonzalez E, Coburn KM, Yu W, Wilson GM, Nurmemmedov E, Kesari S, Chang ET, MacKerell AD, Weber DJ, Carrier F. Small molecules inhibitors of the heterogeneous ribonuclear protein A18 (hnRNP A18): a regulator of protein translation and an immune checkpoint. Nucleic Acids Research. PMID 33398344 DOI: 10.1093/nar/gkaa1254  0.141
2022 Carrillo JA, Kesari S. Is re-radiation for glioblastoma after progression associated with increased survival: to treat or not to treat? Translational Cancer Research. 8: 4-6. PMID 35116726 DOI: 10.21037/tcr.2018.10.22  0.139
2022 Barreyro L, Sampson AM, Ishikawa C, Hueneman KM, Choi K, Pujato MA, Chutipongtanate S, Wyder M, Haffey WD, O'Brien E, Wunderlich M, Ramesh V, Kolb EM, Meydan C, Neelamraju Y, ... ... Kesari S, et al. Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science Translational Medicine. 14: eabb7695. PMID 35263148 DOI: 10.1126/scitranslmed.abb7695  0.136
2014 Tsigelny IF, Kouznetsova VL, Pingle SC, Kesari S. BHLH transcription factors inhibitors for cancer therapy: General features for in silico drug design Current Medicinal Chemistry. 21: 3227-3243. PMID 24735358 DOI: 10.2174/0929867321666140414111333  0.135
2013 Baruah B, Sengupta S, Kesari SP, Ilapakurty B. Pattern of Nonmelanoma Skin Cancers in Sikkim, India: A 3-year Clinicopathological Review. Indian Journal of Otolaryngology and Head and Neck Surgery : Official Publication of the Association of Otolaryngologists of India. 65: 160-2. PMID 24427635 DOI: 10.1007/s12070-013-0652-8  0.134
2012 Mahta A, Kaasam S, Kesari S. IschemIc stroke appearIng as a tumor Translational Neuroscience. 3: 303-304. DOI: 10.2478/s13380-012-0026-9  0.128
2022 Perez JA, Lopez JJ, Torres Badillo CC, Gill J, Kesari S, Novak P, Temnikov M, Byshovets R, Bychkov O. Correction: Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases. Cureus. 14: c78. PMID 36397903 DOI: 10.7759/cureus.c78  0.128
2020 Kim MS, Gernapudi R, Cedeño YC, Polster BM, Martinez R, Shapiro P, Kesari S, Nurmemmedov E, Passaniti A. Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis. Oncotarget. 11: 3863-3885. PMID 33196708 DOI: 10.18632/oncotarget.27743  0.124
2023 Pingle SC, Lin F, Anekoji MS, Patro CPK, Datta S, Jones LD, Kesari S, Ashili S. Exploring the role of cerebrospinal fluid as analyte in neurologic disorders. Future Science Oa. 9: FSO851. PMID 37090492 DOI: 10.2144/fsoa-2023-0006  0.122
2024 Juarez TM, Gill JM, Heng A, Carrillo JA, Wagle N, Nomura N, Nguyen M, Truong J, Dobrawa L, Sivakumar W, Barkhoudarian G, Kelly DF, Kesari S. A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer. Neuro-Oncology Advances. 6: vdae049. PMID 38680990 DOI: 10.1093/noajnl/vdae049  0.12
2010 Dietrich J, Kesari S. Effect of cancer treatment on neural stem and progenitor cells. Cancer Treatment and Research. 150: 81-95. PMID 19834663 DOI: 10.1007/b109924_6  0.117
2021 Yalamanchi M, Sharma A, Nguyen M, Truong J, Carrillo JA, Wagle N, Gill JM, Kesari S. Successful and durable response of primary CNS T-cell lymphoma to upfront temozolomide monotherapy. Leukemia & Lymphoma. 1-5. PMID 33615978 DOI: 10.1080/10428194.2021.1889538  0.117
2020 Larson C, Oronsky B, Goyal S, Ray C, Hedjran F, Hammond TC, Kesari S, Caroen S, Lybeck M, Dobalian VE, Oronsky A, Reid T. COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making. Biochimica Et Biophysica Acta. Reviews On Cancer. 188412. PMID 32827582 DOI: 10.1016/j.bbcan.2020.188412  0.115
2021 T L, H A, M H, O J, J F, L D, M S, Kesari S, S U. Measurements of functional network connectivity using resting state Arterial Spin Labeling during neurosurgery. World Neurosurgery. PMID 34673240 DOI: 10.1016/j.wneu.2021.10.107  0.109
2021 Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, Reid TR. A Review of Persistent Post-COVID Syndrome (PPCS). Clinical Reviews in Allergy & Immunology. PMID 33609255 DOI: 10.1007/s12016-021-08848-3  0.104
2014 Jiang P, Mukthavaram R, Chao Y, Bharati IS, Fogal V, Pastorino S, Cong X, Nomura N, Gallagher M, Abbasi T, Vali S, Pingle SC, Makale M, Kesari S. Correction to novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs [J TranslMed (2014) 12 13] Journal of Translational Medicine. 12. DOI: 10.1186/1479-5876-12-126  0.104
2011 Bhunia GS, Dikhit MR, Kesari S, Sahoo GC, Das P. Role of remote sensing, geographical information system (GIS) and bioinformatics in kala-azar epidemiology. Journal of Biomedical Research. 25: 373-84. PMID 23554714 DOI: 10.1016/S1674-8301(11)60050-X  0.1
2021 Riordan NH, Morales I, Fernández G, Allen N, Fearnot NE, Leckrone ME, Markovich DJ, Mansfield D, Avila D, Patel AN, Kesari S, Rodriguez JP. Correction to: Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. Journal of Translational Medicine. 19: 197. PMID 33971900 DOI: 10.1186/s12967-021-02869-4  0.099
2013 Baruah B, Sengupta S, Ilapakurty B, Kesari SP. A rare case of post septic temporomandibular joint ankylosis Online Journal of Health and Allied Sciences. 12.  0.099
2015 Le AP, Huang Y, Pingle SC, Kesari S, Wang H, Yong RL, Zou H, Friedel RH. Plexin-B2 promotes invasive growth of malignant glioma Oncotarget. 6: 7293-7304.  0.099
2010 Dunbar EM, Kesari S. Gliomas: Current Issues in Diagnosis and Treatment Current Medical Imaging Reviews. 6: 285-294. DOI: 10.2174/157340510793205576  0.097
2016 Alton G, Kesari S. Novel small molecule inhibitors of the OLIG2 transcription factor: promising new therapeutics for glioblastoma. Future Oncology (London, England). 12: 1001-4. PMID 26867754 DOI: 10.2217/fon-2015-0078  0.095
2023 Choudhary A, Yu J, Kouznetsova VL, Kesari S, Tsigelny IF. Two-Stage Deep-Learning Classifier for Diagnostics of Lung Cancer Using Metabolites. Metabolites. 13. PMID 37887380 DOI: 10.3390/metabo13101055  0.095
2021 Junqueira Alves C, Dariolli R, Haydak J, Kang S, Hannah T, Wiener RJ, DeFronzo S, Tejero R, Gusella GL, Ramakrishnan A, Alves Dias R, Wojcinski A, Kesari S, Shen L, Sobie EA, et al. Plexin-B2 orchestrates collective stem cell dynamics via actomyosin contractility, cytoskeletal tension and adhesion. Nature Communications. 12: 6019. PMID 34650052 DOI: 10.1038/s41467-021-26296-7  0.094
2023 Datta S, Lin F, Jones LD, Pingle SC, Kesari S, Ashili S. Traumatic brain injury and immunological outcomes: the double-edged killer. Future Science Oa. 9: FSO864. PMID 37228857 DOI: 10.2144/fsoa-2023-0037  0.094
2014 Saar BG, Freudiger CW, Xu X, Huttner A, Kesari S, Young G, Xie XS. Coherent Raman tissue imaging in the brain. Cold Spring Harbor Protocols. 2014. PMID 24786507 DOI: 10.1101/pdb.top081695  0.09
2023 Yao JZ, Tsigelny IF, Kesari S, Kouznetsova VL. Diagnostics of ovarian cancer via metabolite analysis and machine learning. Integrative Biology : Quantitative Biosciences From Nano to Macro. 15. PMID 37032481 DOI: 10.1093/intbio/zyad005  0.089
2023 Kesari S, Liu A, Gill JM, Nguyen M, Truong J, Nersesian R, Chacon E, Sharma A, Wagle N, Griffiths C, Frazer G, Zats M, Kang S, West MB, Kopke RD, et al. Response to OKN-007 and NAC in a Patient with Unilateral Hearing Loss and Chronic Tinnitus from Vestibular Schwannoma. The International Tinnitus Journal. 27: 40-46. PMID 38050883 DOI: 10.5935/0946-5448.20230007  0.088
2021 Wagle N, Kesari S. Breaking down the blood-brain barrier. Neuro-Oncology. 23: 6. PMID 33277649 DOI: 10.1093/neuonc/noaa274  0.088
2021 Kesari S, Kasper GC, Verkh L, Hammond TC, Matal ML, Hammerling JW, Tankovich N, Lim AP, Zhao KH, Juarez T, Redfern RE, Gill JM, Nomura N, Hiemer A, Heng A, et al. Mesenchymal stem cells in the treatment of severe COVID-19. Translational Medicine Communications. 6: 16. PMID 34395912 DOI: 10.1186/s41231-021-00095-0  0.086
2023 Tsui A, Kouznetsova VL, Kesari S, Fiala M, Tsigelny IF. Role of Senataxin in Amyotrophic Lateral Sclerosis. Journal of Molecular Neuroscience : Mn. PMID 37982993 DOI: 10.1007/s12031-023-02169-0  0.085
2009 Ng K, Nitta M, Lauren H, Kesari S, Kung A, D'Andrea A, Chen CC. A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy Clinical Neurosurgery. 56: 107-118. PMID 20214041  0.084
2009 Kumar V, Kesari S, Dinesh DS, Tiwari AK, Kumar AJ, Kumar R, Singh VP, Das P. A report on the indoor residual spraying (IRS) in the control of Phlebotomus argentipes, the vector of visceral leishmaniasis in Bihar (India): An initiative towards total elimination targeting 2015 (Series-1) Journal of Vector Borne Diseases. 46: 225-229. PMID 19724087  0.084
2021 Dardis C, Donner D, Sanai N, Xiu J, Mittal S, Michelhaugh SK, Pandey M, Kesari S, Heimberger AB, Gatalica Z, Korn MW, Sumrall AL, Phuphanich S. Correction to: Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling. Bmc Neurology. 21: 316. PMID 34391386 DOI: 10.1186/s12883-021-02326-1  0.084
2013 Mahta A, Buhl R, Huang H, Jansen O, Kesari S, Ulmer S. Sellar and supra-sellar glioblastoma masquerading as a pituitary macroadenoma. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 34: 605-7. PMID 22569569 DOI: 10.1007/s10072-012-1110-1  0.084
2021 Kesari SP, Paul S, Dey R. To Study the Burden and Risk Factors for Chronic Suppurative Otitis Media in a Population of Sikkim, India: A Hospital Based Study. Indian Journal of Otolaryngology and Head and Neck Surgery : Official Publication of the Association of Otolaryngologists of India. 74: 4117-4124. PMID 36742467 DOI: 10.1007/s12070-021-02855-8  0.082
2010 Picado A, Das ML, Kumar V, Kesari S, Dinesh DS, Roy L, Rijal S, Das P, Rowland M, Sundar S, Coosemans M, Boelaert M, Davies CR. Effect of village-wide use of long-lasting insecticidal nets on visceral Leishmaniasis vectors in India and Nepal: A cluster randomized trial Plos Neglected Tropical Diseases. 4. PMID 20126269 DOI: 10.1371/Journal.Pntd.0000587  0.081
2009 Kumar V, Kesari S, Kumar AJ, Dinesh DS, Ranjan A, Prasad M, Sinha NK, Kumar R, Das P. Vector density and the control of kala-azar in Bihar, India. Memã³Rias Do Instituto Oswaldo Cruz. 104: 1019-22. PMID 20027471  0.081
2021 Szu J, Wojcinski A, Jiang P, Kesari S. Impact of the Olig Family on Neurodevelopmental Disorders. Frontiers in Neuroscience. 15: 659601. PMID 33859549 DOI: 10.3389/fnins.2021.659601  0.079
2020 Lin F, Ichim TE, Pingle S, Jones LD, Kesari S, Ashili S. Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome. World Journal of Stem Cells. 12: 1067-1079. PMID 33178392 DOI: 10.4252/wjsc.v12.i10.1067  0.078
2023 Kuang A, Kouznetsova VL, Kesari S, Tsigelny IF. Diagnostics of Thyroid Cancer Using Machine Learning and Metabolomics. Metabolites. 14. PMID 38248814 DOI: 10.3390/metabo14010011  0.078
2022 Meysami S, Raji CA, Glatt RM, Popa ES, Ganapathi AS, Bookheimer T, Slyapich CB, Pierce KP, Richards CJ, Lampa MG, Gill JM, Rapozo MK, Hodes JF, Tongson YM, Wong CL, ... ... Kesari S, et al. Handgrip Strength is Related to Hippocampal and Lobar Brain Volumes in a Cohort of Cognitively Impaired Older Adults with Confirmed Amyloid Burden. Journal of Alzheimer's Disease : Jad. PMID 36530088 DOI: 10.3233/JAD-220886  0.077
2017 Minetto MA, D'Angelo V, Arvat E, Kesari S. Diagnostic work-up in steroid myopathy. Endocrine. 60: 219-223. PMID 29143179 DOI: 10.1007/s12020-017-1472-5  0.075
2021 Kesari S, Kasper GC, Verkh L, Hammond TC, Matal ML, Hammerling JW, Tankovich N, Lim AP, Zhao KH, Juarez T, Redfern RE, Gill JM, Nomura N, Hiemer A, Heng A, et al. Correction to: Mesenchymal stem cells in the treatment of severe COVID-19. Translational Medicine Communications. 6: 19. PMID 34458585 DOI: 10.1186/s41231-021-00098-x  0.073
2018 Minetto MA, Caresio C, D'Angelo V, Lanfranco F, Ghizzoni L, Roatta S, Arvat E, Kesari S. Diagnostic evaluation in steroid-induced myopathy: case report suggesting clinical utility of quantitative muscle ultrasonography. Endocrine Research. 43: 235-245. PMID 29648902 DOI: 10.1080/07435800.2018.1461904  0.072
2009 Wüthrich C, Cheng YM, Joseph JT, Kesari S, Beckwith C, Stopa E, Bell JE, Koralnik IJ. Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. Journal of Neuropathology and Experimental Neurology. 68: 15-25. PMID 19104450 DOI: 10.1097/Nen.0B013E3181912570  0.072
2012 Bhunia GS, Kesari S, Chatterjee N, Kumar V, Das P. Telehealth: a perspective approach for visceral leishmaniasis (kala-azar) control in India. Pathogens and Global Health. 106: 150-8. PMID 23265372 DOI: 10.1179/2047773212Y.0000000014  0.072
2016 Kesari SP, Basnett B, Chettri A. Spectrum of Tuberculous Infection in Patients Suffering from HIV/AIDS and Its Correlation with CD-4 Counts: A Retrospective Study from Sikkim. Indian Journal of Otolaryngology and Head and Neck Surgery : Official Publication of the Association of Otolaryngologists of India. 71: 167-171. PMID 31275824 DOI: 10.1007/s12070-016-1001-5  0.071
Hide low-probability matches.